書籍詳細

炎症リウマチ

P.16 掲載の参考文献

• 1) Calin A: Spondylarthritis. Medicine Sci Am p15, III6, 1982

• 2) 辻本正記: 潰瘍性大腸炎とspondylarthritis. リウマチ病セミナーI (七川歡次編), pp61-70, 永井書店, 大阪, 1990

• 3) 守田則一ら: IBDの全国疫学調査 (第2報): クローン病の疫学的研究.厚生省特定疾患難治性炎症性腸管障害調査研究班, 平成4年度研究報告書, pp. 149-152, 1993

• 4) 守田則一: わが国における特発性炎症性腸疾患の疫学. 医学のあゆみ178: 487-490, 1996

• 5) Mayer L, Fanowitz HD: Extra-intestinal manifestations of ulcerative colitis including reference to Crohn's disease. In Inflammatory Bowel Disease (Ed, Allan RN, Keighley MRB, Wiliams JA & Hawkins C), pp121-130, New York, Churchil Livingstone, 1983

• 6) Weiner SR, Clarke J, Taggart NA, et al: Rheumatic manifestations of inflammatory bowel disease. Sem Arthritis Rheum 20: 353-366, 1991

• 7) Maeda K, Okada M, Yao T, et al: Intestinal and extraintestinal complications of Crohn's disease: predictors and cumulative probability of complications, J Gastroenterol 29: 577-582, 1994
  pubmed

• 8) Snook JA: Extra-intestinal manifestations of Crohn's disease. Top Gastroenterol 17: 175-186, 1990

• 9) Pallone F, Boirivant M, Stazi MA, et al: Analysis of clinical course of postoperative recurrence in Crohn's disease of distal ileum. Dig Dis Sci 37: 215-219, 1992
  pubmed

• 10) McEniff N, Eustace S, McCarthy C, et al: Asymptomatic sacroiliitis in inflammatory bowel disease assessment by computed tomography. Clin Imaging 19: 258-262, 1995

• 11) Wright V, Watkinson G: Sacro-iliitis and ulcerative colitis. Br Med J 2: 675-680, 1965
  pubmed

• 12) Haslock I, Wright V: The musculoskeletal complications of Crohn's disease, Medicine 52: 217-225, 1973
  pubmed

• 13) Leirisalo-Repo M, Turunen U, Stenman S, et al: High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 37: 23-31, 1994
  pubmed

• 14) De Vos M, Cuvelier C, Mielants H, et al: Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 96: 339-344, 1989
  pubmed

• 15) Cuvelier C, Barbatis C, Mielants H, et al: Histopathology of intestinal inflammation related to reactive arthritis. Gut 28: 394-401, 1987
  pubmed

• 16) Mielants H, Veys EM, Cuvelier C, et al: Ileocolonoscopic findings in seronegative spondylarth-ropathies. Brit J Rheumatol 27: 95-105, 1988

• 17) Mielants H, De Vos M, Goemaere S, et al: Intestinal mucosal permeability in inflammatory rheumatic disease. II. Role of disease. J Rheumatol 18: 394-400, 1991

• 18) Altomonte L, Zoli A, Veneziani A, et al: Clinical silent inflammatory gut lesions in undifferentiated spondylarthropathies. Clin Rheumatol 13: 565-570, 1994
  pubmed

• 19) Wood AJJ: Drug therapy. Inflammatory bowel disease. N Engl J Med 334: 841-848, 1996

• 20) 渡辺晃: クローン病治療指針 (案) の作成.厚生省特定疾患消化吸収障害調査研究班, 昭和60年度業績集, pp 20-21, 1986

• 21) Wilschanski M, Sherman P, Pencharz P, et al: Supplementary enteral nutrition maintains remissionin paediatric Crohn's disease. Gut 38: 543-548, 1996

• 22) Prantera C, Zannoni F, Scribano ML, et al: An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 91: 328-332, 1996
  pubmed

• 23) Lavy A: Triamcinolone improves outcome in Crohn's disease strictures. Dis Colon Rectum 40: 184-186, 1997
  pubmed

• 24) Bouhnik Y, Lemann M, Mary JY, et al; Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347: 215-219, 1996

• 25) Sandborn WJ, Tremaine WJ, Lawson GM: Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high dose oral cyclosporine. Am J Gastroenterol 91: 37-43, 1996

• 26) Van Dullemen HM, et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimericmonoclonal antibody (cA 2). Gastroenterology 109: 129 135, 1995

• 27) Lerebours E, et al: Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Gastroenterology 107: 357-361, 1994
  pubmed

• 28) Sawada K, Ohnishi K, Kosaka T, et al: Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol 30 [suppl VII]: 124-127, 1995

• 29) Parronchi P, Romagnani P, Annunziato F, et al: Type 1 T-helper cell predominance andinterleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 150: 823-832, 1997

• 30) Watanabe M, et al: Preferential activation of CD4+V β5.2/5.3+ intestinal intraepithelial lymphocytes in the inflamed lesions of Crohn's disease. Clin Immunol Immunopathol 78: 130-139, 1996

• 31) 松本誉之, 小林絢三: 炎症性腸疾患におけるT細胞抗原レセプターの意義.医学のあゆみ178: 575-579, 1996

• 32) Dekker-Saeys BJ, Meuwissen SGM, Van Den Berg-Loonen EM, et al: Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 37: 33-35, 1978

• 33) Mielants H, Veys EM, Cuvelier C, et al: Ileocolonoscopic findings in seronegative spondylarthropathies. Brit J Rheumatol 27 [suppl II]: 95-105, 1988

• 34) Nakajima A, Matsuhashi N, Kodama T, et al: HLA-linked susceptibility and resistance genes in Crohn's disease. Gastroenterology 109: 1462-1467, 1995
  pubmed

• 35) Toyoda H, Wang SJ, Yang HY, et al: Distinct associations of HLA class H genes with inflammatory bowel disease. Gastroenterology 104: 741-748, 1993

• 36) Satsangi J, Welsh KI, Bunce M, et al: Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 347: 1212-1217, 1996
  pubmed

• 37) Hugot JP, Laurent-Pulg P, Gower-Rousseau C, et al: Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379: 821-823, 1996

• 38) Ekbom A, Daszak P, Kraaz W, et al: Crohn's disease after in utero maeasles virus exposure. Lancet 348: 515-517, 1996
  pubmed

• 39) Thompson NP, Montgomery SM, Pounder RE, et al: Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 345: 1071-1074, 1995
  pubmed

• 40) Wakefield AJ, Sim R, Akbar AN, et al: In site immune responses in Crohn's disease: a comparison with acute and persistent measles virus infection. J Med Virol 51: 90-100, 1997

• 41) Iizuka M, Nakagomi O, Chiba M, et al: Absence of measles virus in Crohn' s disease. Lancet 345: 199, 1995
  pubmed

• 42) Haga Y, Funakoshi O, Kuroe K, et al: Absence of measles viral genomic sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction. Gut 38: 211-215, 1996
  pubmed

• 43) Jones P, Fine P, Piracha S: Crohn's disease and rneasles. Lancet 349: 473, 1997
  pubmed

• 44) Salmi M, Andrew DP, Butcher EC, et al: Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: Dissection of the molecular mechanisms. J Exp Med 181: 137-149, 1995
  pubmed

P.25 掲載の参考文献

• 1) McCarty DJ, O'Duffy JD, Pearson L, et al: Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 254: 2763-2767, 1985
  pubmed

• 2) Russell EB, Hunter JB, Pearson L, et al: Remitting seronegative seronegative symmetrical synovitis with pitting edema-13 additional cases. J Rheumatol 17: 633-639, 1990

• 3) Chaouat D, Belange G, Leparc JM, et al: Benign acute edematous polyarthritis in the elderly. Apropos of 4 cases. Rev Rhum Mal Osteoartic 55: 895-899, 1988
  pubmed

• 4) Schaeverbeke T, Vernhes JP, Bannwarth B, et al: Is remitting seronegative symmetrical synovitis with pitting oedema (RS3PE syndrome) associated with HLA-A2? [letter]: Br J Rheumatol 34: 889-890, 1995
  pubmed

• 5) Russell EB, McCarty DJ, Schwab J, et al: RS3PE syndrome: no evidence for retroviruses. J Rheumatol 21: 1105-1106, 1994
  pubmed

• 6) 佐野元昭, 岡本晋, 山脇健盛ら: Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) 症候群の2症例, リウマチ37: 493-498, 1997

• 7) Healey LA: RS3PE syndrome (letter). J Rheumatol 17: 414, 1990

• 8) Oliveri I, Salvarani C, Cantini F: Remitting distal extremity swelling with pitting edema: adistinct syndrome or a clinical feature of different inflammatory rheumatic diseases? J Rheumatol 24: 249-252, 1997
  pubmed

• 9) Koeger AC, Karmochkine M, Chaibi P: RS3PE syndrome associated with advanced ankylosing spondylitis [letter]. J Rheumatol 22: 375-376, 1995
  pubmed

• 10) 山西裕司, 峠岡康幸, 椋園宏ら: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome) と鑑別を要した慢性関節リウマチおよび全身性エリテマトーデス様病態合併の2症例. リウマチ33: 162-168, 1993

• 11) Olivo D, D: Amore M, Lacava R, et al: Benign edematous polysynovitis in the elderly (RS3PE syndrome). Clin Exp Rheumatol 12: 669-673, 1994
  pubmed

• 12) Billey T, Navaux F, Lassoued S: Remitting seronegative symmetrical synovitis with pitting edema (RS 3 PE) as the first manifestations of periarteritis nodosa. Report of a case. Rev Rhum [Engl Ed] 62: 53-54, 1995

• 13) Hernandez-Beriain, Cuesta-Callardo I, Segura-Garcia C: Remitting seronegative symmetrical synovitis with pitting edema: a rheumatic manifestation of myeldysplastic syndrome? Rev Rhum [Engl Ed] 63: 629-632, 1996
  pubmed

• 14) Cantini F, Niccoli L, Olivieri I, et al: Remitting distal lower extremity swelling with pitting edemain acute sarcoidosis. Ann Rheum Dis 56: 565-572, 1997

• 15) Olivieri I, Padula A, Favaro L, et al: RS3PE syndrome with unilateral involvement [letter;comment]. J Rheumatol 21: 372, 1994
  pubmed

• 16) Pariser KM, Canoso JJ: Remitting, seronegative (A) symmetrical synovitis with pitting edematwo cases of RS3PE syndrome [see comments]. J Rheumatol 18: 1260-1262, 1991

• 17) Schaeverbeke T, Fatout E, Marce S, et al: Remitting seronegative symmetrical synovitis with pitting oedema: disease or syndrome? Ann Rheum Dis 54: 681-684, 1995
  pubmed

• 18) Olive A, Blanco JD, Pons M, et al: The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol 24: 333-336, 1997

• 19) 前田晃: 亜急性関節リウマチについて. リウマチ病セミナーVI (七川歡次監修), 大阪, 永井書店, pp15-20, 1995

P.31 掲載の参考文献

• 1) Silman AJ, Hochberg MC: Epidemiology of the rheumatic diseases. Oxford, Oxford Medical Publications, 1993

• 2) Persellin RH: The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 27: 922-927, 1976
  pubmed

• 3) Masi AT, Feigenbaum SL, Chatterton RT: Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Semin Arthritis Rheum 25: 1-27, 1995
  pubmed

• 4) Pritchard MH: An examination of the role of female hormones and pregnancy as risk factor for rheumatoid arthritis, using a male population as control group. Br J Rheumatol 31: 395-399, 1992
  pubmed

• 5) Goemaere S, Ackerman C, Goethals, et al: Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 17: 1620-1622, 1990
  pubmed

• 6) Goldstein R: Functional assessment and symptoms of rheumatoid arthritis in relation to menstrual cycle phase. J Rheumatol 14: 395-396, 1987
  pubmed

• 7) 村田紀和: 結合組織病と妊娠. リウマチ病セミナーII (七川歡次監修), pp17-24, 永井書店, 大阪, 1991

• 8) Silman AJ, Roman E, Veral V, et al: Adverse reproductive outcomes in women who subsequently develop rheumatoid arthritis. Ann Rheum Dis 47: 979-981, 1988

• 9) Lansink M, de Boer A, Dijkmans B, et al: The onset of rheumatoid arthritis in relation to pregnancy and child birth. Clin Exp Rheumatol 11: 171-174, 1993

• 10) Silman A, Kay A, Brennan P: Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 35: 152-155, 1992

• 11) Brennan P, Silman A: Breast-feeding and the onset of rheumatoid arthrits. Arthrits Rheum 37: 808-813, 1994

• 12) Silman AJ: Is pregnancy a risk factor in the causation of rheumatoid arthritis? Ann Rheum Dis 5: 1031-1034, 1986

• 13) Hazes JMV, Dijkmans BAC, Vandenbroucke JP, et al: Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum 33: 1770-1775, 1990

• 14) Spector TD, Roman E, Silman AJ: The pill, parity and rheumatoid arthritis. Arthritis Rheum 33: 782-789, 1990
  pubmed

• 15) Siamopoulou-Mavridou A, Manoussakis MN, Mavridis AK, et al: Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset, Ann Rheum Dis 47: 982-987, 1988
  pubmed

• 16) Nelson JL, Koepsell TD, Dugowson CE, et al: Fecundity before disease onset in women with rheumatoid arthritis. Arthritis Rheum 36: 7-14, 1993
  pubmed

• 17) Masi AT: Sex hormones and rheumatoid arthritis: cause or effect relationships in a complex pathology? Clin Exp Rheumatol 13: 227-240, 1995

• 18) Deighton CM, Watson MJ, Walker DJ: Sex hormones in postmenopausal HLA-identical rheumatoid arthritis discordant sibling pairs. J Rheumatol 19: 1663-1667, 1992

• 19) Masi AT, Chatterton RT, Comstock GW, et al: Decreased serum dehydroepiandrosterone sulfate (DHAS) levels before onset of RA in younger, premenopausal women: acontrolled, prospectivestudy. Arthritis Rheum 37: S315 (Abstract), 1994

• 20) Cutolo M, Accardo S: Sex hormones, HLA and rheumatoid arthritis. Clin Exp Rheumatol 9: 641-646, 1991
  pubmed

• 21) Ollier W, Spector TD, Gilrnan A, et al: Are certain HLA haplotypes responsible for low testosterone levels in males? Dis Markers 7: 139-143, 1989

• 22) Raum D, Awdeh Z, Glass D, et al: Extended haplotypes of chromosome 6 in adult rheumatoid arthritis. Arthritis Rheum 27: 516-521, 1984
  pubmed

• 23) Jansson L, Holmdahl R: Oestrogen-induced suppression of collagen arthritis; 17 β-estradiol istherapeutically active in normal and castrated FI hybrid mice of both sexes. Clin Exp Immunol 89: 446-451, 1992

• 24) Harbuz MS, Perveen-Gill Z, Lightman SL, et al: Protective role for testosterone in adjuvant-induced arthritis. Br J Rheumatol 34: 1117-1122, 1995
  pubmed

• 25) van den Brink HR, van Everdingen AA, van Wijk MJG, et al: Adjuvant oestrogen therapy does notimprove disease activity in postmenopausal patients with rheumatoid arthritis, Ann Rheum Dis 52: 862-865, 1993

• 26) Cotolo M, Balleari E, Giusti M, et al: Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 34: 1-5, 1991

• 27) Schuurs AH, Verheul HA: Effects of gender and sex steroids on the immune response. J Steroid Biochem 35: 157-172, 1990
  pubmed

• 28) Masi AT, Feigenbaum SL, Chatterton RT, et al: Integrated hormonal-immunological vascular (HIV triad) systems interactions in rheumatic diseases. Clin Exp Rheumatol 13: 203-216, 1995

• 29) Cutolo M, Accardo S, Villaggio B, et al: Evidence for the presence of androgen receptors in thesynovial tissue of rheumatoid arthritis patients and healthy controls. Arthritis Rheum 35: 1007-1015, 1992
  pubmed

• 30) Cutolo M, Accardo S, Villaggio B, et al: Presence of estrogen-binding sites on macrophage-likesynoviocytes and CD8+, CD29+, CD45RO+ T lymphocytes in normal and rheumatoid synovium. Arthritis Rheum 36: 1087 1097, 1993

• 31) Ushiyama T, Inoue K, Nishioka J: Expression of estrogen receptor related protein (p29) andestradiol binding in human arthritic synovium, J Rheumatol 22: 421-426, 1995

• 32) Young PCM, Stack MT: Estrogen and glucocorticoid receptors in adult canine articular cartilage. Arthritis Rheum 25: 568-573, 1982

• 33) Rosner IA, Manni A, Malemud CJ, et al: Estradiol receptors in articular chondrocytes. Biochem Biophys Res Comm 106: 1378-1382, 1982
  pubmed

• 34) Carrascosa A, Audi L, Ferrandez MA, et al: Biological effects of androgens and identification of specific dihydrotestosterone-binding sites in cultured human felal epiphyseal chondrocytes. J Clin Endocrinol Metab 70: 134-140, 1990
  pubmed

• 35) Guerne PA, Carson DA, Lotz M: IL-6 production by human articular chondrocytes. J Immunol 144: 499-505, 1990
  pubmed

• 36) Hill SM, Fuqua SAW, Chamness GC, et al: Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res 49: 145-148, 1989

• 37) Yaich L, Dupont WD, Cavener DR, et al: Analysis of the Pvu II restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 52: 77-83, 1992

• 38) Kobayashi S, Inoue S, Hosoi T, et al: Association of bone mineral density with polymorphism of estrogen receptor gene. J Bone Miner Res 11: 306-311, 1996

P.40 掲載の参考文献

• 1) Bezecny R: Dermatomyositis. Arch Dermatol 171: 242-251, 1935

• 2) Kagen LT: Polymyositis/Dermatomyositis. In Arthritis and Allied Conditions (Eds, MaCarty DJ, Koopman WJ), pp1225-1252, Philadelphia, Lea and Febiger, 1993

• 3) Bohan A, Peter JB: Polymyositis and dermatomyositis (First of two parts). N Engl J Med 292: 344-347, 1975
  pubmed

• 4) Sigurgeirsson B, Lindelof B, Edhag O, et al: Risk of cancer in patients with dermatomyositis or polymyositis;a population-based study. N Engl J Med 326: 363-367, 1992
  pubmed

• 5) Chow WH, Gridley G, Mellemkjae r L, et al: Cancer risk following polymyositis and dermatomyositis: anationwide cohort study in Denmark. Cancer Causes and Control 6: 9-13, 1995

• 6) Airio a, Pukkala E, Isomaki H: Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22: 1300-1303, 1995
  pubmed

• 7) Lakhanpal S, Bunch TW, Ilustrup DM, et al: Polymyositis-dermatomyositis and malignant lesios: does an association exist? Mayo Clin Proc 61: 645-653, 1986

• 8) Manchul LA, Jin A, Pritchard KI, et al.: The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis: a controlled study. Arch Intern Med 145: 1835-1839, 1985
  pubmed

• 9) Bohan A, Peter JB, Bowman RL, et al: A computer assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56: 255-286, 1977
  pubmed

• 10) Callen JP, Hyla JF, Bole GG, et al; The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol 116: 295-298, 1980
  pubmed

• 11) Masi AT, Hochberg MC: Temporal association of polymyositis-dermatomyositis with malignancy: methodologic and clinical considerations. Mt Sinai J Med 55: 471-478, 1988
  pubmed

• 12) Koh ET, Seow A, Ong B, et al: Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 52: 857-861, 1993
  pubmed

• 13) Verducci MA, Malkasian GD, Friedman SJ, et al: Gynecologic carcinoma associated with dermatomyositis-polymyositis. Obstet Gynecol 64: 695-698, 1984
  pubmed

• 14) Callen JP: The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 6: 253-259, 1982
  pubmed

• 15) Callen JP: Relationship of cancer to inflammatory muscle diseases; dermatomyositis, polyrnyositis, and inclusion body myositis. Rheum Dis Clin North Am 20: 943-953, 1994
  pubmed

• 16) Engel AG, Arahata K: Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 17: 704-721, 1986
  pubmed

• 17) 谷本潔昭, 狩野庄吾, 森俊二ら: 皮膚筋炎, 多発 (性) 筋炎調査表の診断基準案. 日本医事新報3452: 25-31, 1990

P.49 掲載の参考文献

• 1) Sjogren H: Zur Kenntnis der keratoconjunctivitis sicca, Acta Ophthal 11 (suppl 2): 1, 1933

• 2) Miyasaka N, et al: Possible involvement of EBV in polyclonal B cell activation in Sjogren's syndrome. Academic Press, London: 119, 1988

• 3) Green JE, et al: Exocrinopathy resembling Sjogren's syndrome in HTLV-1 tax transgenic mice. Nature 341: 72-74, 1989
  pubmed

• 4) Iwakura Y, et al: Inflammatory polyarthritis in mice transgenic for human T cell leukemia virus type I. Arthritis Rheum 36: 1612-1620, 1993
  pubmed

• 5) 村田紀和ら: Sjogren症候群と骨関節症状. リウマチ病セミナーVI, pp51-57, 1995

• 6) Talal N: Sjogren syndrome and pseudolymphoma. Hosp Pract Off Ed 30: 71-75, 1988

• 7) Moutsopoulos HM, Chused TM, Mann DL, et al: Sjogren's syndrome (sicca syndrome): current issues. Ann Intern Med 92 (part I): 212, 1980

• 8) Moutsopoulos HM: Sjogren's sydrome therapy: future directions. J Rheumatol 24 (suppl 50): 33-34, 1997

P.58 掲載の参考文献

• 1) Sharp GC, Irvin WS: Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52 148, 1972

• 2) 粕川禮司: MCTDの概念誕生の背景とその歴史. 日本内科学会雑誌85: 1191-1195, 1996

• 3) 志水正敏: MCTDの臨床症状. 日本内科学会雑誌85: 1208-1212, 1996

• 4) 近藤啓文, 高橋道雄, 東條毅: MCTDの臨床経過についてのプロジェクト研究 (第1報). 厚生省特定疾患混合性結合組織病調査研究班, 平成6年度研究報告書, pp12-14, 1995

• 5) 東條毅, 小笠原孝, 青塚新一ら: 混合性結合組織病の主死因と5年生存率.厚生省特定疾患混合性結合組織病調査研究班, 平成2年度研究報告書, pp10-12, 1991

• 6) Reichlin M: Problems in differentiation of SLE and mixed connective tissue disease. N Engl J Med 21: 1194, 1976

• 7) Le Roy EC, et al: Undifferentiated connective tissue syndrome. Arthritis Rheum 23: 341, 1980

• 8) Tan EM: Antinuclear Antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Imm 44: 93-151, 1989

• 9) Doria A, Ghirardello A, de Zambiasi P, et al: Division of rheumatology. J Rheumatol 19: 259. 264, 1992

• 10) 二森経世: MCTDの病因と発症機序. 日本内科学会雑誌85: 1196 1202, 1996

• 11) 国枝武義: 混合性結合組織病特殊な病態の臨床と治療;肺高血圧症, 日本内科学会雑誌85: 1237-1243, 1996

P.62 掲載の参考文献

• 1) Morales A: Intravesical therapy of bladder cancer: An immunotherapy success story. Int J Urol 3: 329-333, 1996
  pubmed

• 2) 山田拓己: 表在癌の悪性進展, ABH抗原. 病理と臨床14: 467-471, 1996

• 3) Hudson MA, Herr HW: Carcinoma in situ of the bladder. J Urol 153: 564-572, 1995
  pubmed

• 4) Stricker PD, Grant ABF, Hosken BM, et al: Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. J Urol 143: 34-35, 1990

• 5) Morales A, Edinger D, Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976

• 6) Akaza H, Hinotsu S, Aso Y, et al: Bacillus Calmette-Guerin treatment of exsting papillary bladder cancer and carcinoma in situ of the bladder. Cancer 75: 552-559, 1995

• 7) 原田泰規, 瀬口利信, 野々村祝夫ら: 膀胱上皮内癌の臨床的検討, 第84回日本泌尿器科学会報告, 1996

• 8) Lamm DL, Meijden APM, Morales A, et al: Incidence and treatment of complications of BCGintravesical therapy for superficial bladder cancer. J Urol 147: 596-600, 1992

• 9) Hughes RA, Allard SA, Maini RN: Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. Ann Rheum Dis 48: 432-434, 1989
  pubmed

• 10) Ochsenkuhn T, Weber MM, Caselmann WH: Arthritis after Mycobacterium bovis immunotherapyfor bladder cancer. Ann Int Med 112: 882,1990

• 11) Puett DW, Fuchs HA: Arthritis after Bacillus Calmette-Guerin therapy. Ann Int Med 117: 537, 1992
  pubmed

• 12) Goupille P, Soutsif D, Valat J-P: Arthritis after Calmette-Guerin Bacillus immunotherapy forbladder cancer. J Rheumatol 19: 1825-1826, 1992

• 13) Chapman PT, Mark SD, Moller PW: Arthritis associated with adjuvant mycobacterial treatmentfor carcinoma of the bladder. NZ Med J 105: 37-38, 1992

• 14) Van Thiel RJ, Nossent GD, Tjonpian-Gi NP: Articular complications of intravesical BCG treatment for bladder carcinoma. Brit J Urol 70: 446-447, 1992

• 15) Chazerain P, Desplaces N, Mamoudy P, et al: Prosthetic total knee infection with a Bacillus Calmette Guerin (BCG) strain after BCG therapy for bladder cancer, J Rheumatol 20: 2171-2172, 1993
  pubmed

• 16) Belmatoug N, Levy-Djebbour S, Appelboom T, et al: Polyarthritis in four patients treated with intravesical BCG therapy for bladder carcinoma. Rev Rheum 60: 162-166, 1993

• 17) Devlin M, Deodhar A, Davis M: Arthritis as a complication of intravesical BCG vaccine. Brit Med J 308: 1638, 1994
  pubmed

• 18) Price GE: Arthritis and irits after BCG therapy for bladder cancer. J Rheumatol 21: 564-565, 1994

• 19) Hammadeh MY, Dutta SN, Worrall JG, et al: Acute reactive polyarthritis after intravesical bacillus Calmette-Guerin instillation Brit J Uro 76: 811-812, 1995

• 20) Res PC, Schaar CG, Breedveld FC, et al: Synovial fluid T cell reactivity against 65kD heat shock protein of mycobacteria in early chronic arthritis. Lancet 27: 478-580, 1988

• 21) Li S-G, Quayle AJ, Shen Y et al: Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation.: Arthritis Rheum 35: 270-281, 1992
  pubmed

P.69 掲載の参考文献

• 1) Hunder GG, et al: The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction. Arthritis Rheum 33: 1065-1067, 1990
  pubmed

• 2) Jennette JC, et al: Nomenclature of systemic vasculitis. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994
  pubmed

• 3) Jones RE Jr: Questions to the editorial board and other authorities. Am J Dermatopathol 7: 181-187, 1985

• 4) Olsen TG: Vasculitis, In: Pathology of the skin (Ed, Farmer ER, Hood AF), pp175-192, Norwalk, CT, Appleton & Lange, 1990.

• 5) Gibson LE, Su WPD: Cutaneous vasculitis. Rheum Dis Clin North Am 21 (4): 1097-1113, 1995

• 6) Carlson JA, Mihm MCJ, LeBoit PE: Cutaneous lymphocytic vasculitis: a definition, a review, and aproposed classification. Semin Diagn Pathol 13: 72-90, 1996

• 7) Barnhill RL, Busam KJ: Vascular diseases. In: Lever's Histopathology of the Skin (Ed, Elder), pp185-208, Eighth Edition, Philadelphia, Lippincott-Raven, 1997

骨関節, 脊椎, 神経

P.80 掲載の参考文献

• 1) Gamble JS, Simmons SC, Freedman M: The symphysis pubis. Anatomic and pathologic considerations. Clin Orthop 203: 261-272, 1986

• 2) Gorham LW, Stout AP: Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone). J Bone and Joint Surg 37-A: 985-1004, 1955

• 3) Cahill BR, Osteolysis of the distal part of the clavicle in male athletes. J Bone and Jint Surg 64-A: 1053-1058, 1982

• 4) Herscovici D Jr, Bowen JR, Scott CI Jr: Cervical instability as an unusual manifestation of Hajdu Cheney syndrome of acroosteolysis. Clin Orthop 255: 111-116, 1990
  pubmed

• 5) Albertsen AM, Egund N, Jurik AG, et al: Posttraumatic osteolysis of the pubic bone simulating rnalignancy. Acta Radiol 35: 40-44, 1994
  pubmed

• 6) An HS, Jackson WT, Hawthorne KB: Osteolysis of the pubic bone simulating malignancy. Orthopedics 11: 951-954, 1988.
  pubmed

• 7) Casey D, Mirra J, Staple TW: Parasymphyseal insufficiency fracture of the os pubis. AJR 42: 581-586, 1984

• 8) Jones AR, Lachiewicz PF: Pathologic Malgaigne fracture following pelvic irradiation. A case report. Clin Orthop 221: 226-230, 1987
  pubmed

• 9) Goergen TG, Resnick D, Riley RR: Post-traumatic abnormalities of the pubic bone simulating malignancy. Radiology 126: 85-87, 1978
  pubmed

• 10) Hall FM, Goldberg RP, Kadson EJ, et al: Post-traumatic osteolysis of the pubic bone simulating a malignant lesion. J Bone Joint Surg 66-A: 121-126, 1984

• 11) McGuigan LE, Edmonds JP, Painter DM: Pubic osteolysis. J Bone Joint Surg 66A: 127-129, 1984

• 12) McCarthy B, Dorfman HD: Pubic osteolysis. A benign lesion of the pelvis closely mimicking a malignant neoplasm. Clin Orthop 251: 300-307, 1990
  pubmed

• 13) Ramon R, Sebastian G, Segar JM, et al: Pubic osteolysis simulating a malignant lesion: case report. J Trauma 36: 597-598, 1994

• 14) Rask MR: Fatigue fracture ossa pubes due to obesity: report of a case. Clin Orthop 142: 182-184, 1979
  pubmed

• 15) Matsumoto K, Hukuda S, Ishizawa M, et al: Pubic osteolysis mirnicking a malignant lesion. A case report with a fracture dislocation of sacroiliac joint. Skeletal Radiol 26: 438-444, 1997
  pubmed

• 16) Onnerfaet R, Brisrnar J: Stable pubic fractures in the elderly. The association with sacroiliac injuries. Int Orthop (SICOT) 13: 143-145, 1989

P.90 掲載の参考文献

• 1) Goto M, Rubenstein M, Weber J, et al: Genetic linkage of Werner's syndrome to five markers on chromosome 8. Nature 335: 735-738, 1992

• 2) Yu C-E, Oshima J, Fu Y-H, et al: Positional cloning of the Werner's syndrome gene. Science 272: 258-261, 1996

• 3) Goto M, Tanimoto K, Horiuchi Y, et al: Family analysis of Werner's syndrome: asurvey of 42 Japanese families with a review of the literature. Clin Genet 19: 8-15, 1981

• 4) Goto M: Hierarchical deterioration of body systems in Werner's syndrome: applications for normal ageing. Mech Age Dev (in press)

• 5) Goto M, Horiuchi Y, Tanimoto K, et al: Werner's syndrome: analysis of 15 cases with a review of the Japanese literature. J Am Geriat Soc 26: 341-357, 1978
  pubmed

• 6) Goto M, Horiuchi Y, Okumura K, et al: Immunological abnormalities of aging: an analysis of T lymphocyte subpopulations of Werner's syndrome. J Clin Invest 64: 695-699, 1979
  pubmed

• 7) Goto M, Tanimoto K, Aotsuka S, et al: Age-related changes in auto-and natural antibody in the Werner's syndrome. Am J Med 72: 607-614, 1982
  pubmed

• 8) Goto M, Tanimoto K, Horiuchi Y, et al: Reduced natural killer cell activity of lymphocytes from patients with Werner's syndrome and recovery of its activity by purified human leukocyte inter-feron. Scand J Immunol 15: 389-397, 1983

• 9) Goto M: Immunosenescent features of segmental progeroid syndrome: Werner's syndrome. AGEING Immunol Infect Dis 3: 203-213, 1992

• 10) Goto M, Miller RW, Ishikawa Y, et al: Excess of rare cancers in Werner's syndrome (adult progeria). Cancer Epidemiol Biomarker Prevent 5: 239-246, 1996

• 11) Goto M, Murata K: Urinary excretion of macromolecular acidic glycosaminoglycans in Werner's syndrome. Clin Chem Acta 85: 101-106, 1978

• 12) 後藤真: ヒアルロン酸の生理的役割と疾患. 炎症15: 105-113, 1995

P.99 掲載の参考文献

• 1) 細見新次郎:関節唇の構造と機能. 関節外科13: 295-301, 1994

• 2) 東博彦, 田辺秀樹: 寛骨臼関節唇の形態と加齢変化. 関節外科13: 307-315, 1994

• 3) 東博彦: 寛骨臼関節唇;総論. 関節外科13: 293-294, 1994

• 4) 平澤泰介, 岡島誠一郎, 佐藤弘明ら: 変形性膝関節症の疼痛因子. 整・災外38: 39-46, 1995

• 5) 玉井幹人, 黒川正夫, 岡島誠一郎ら: 肩関節包の神経終末に関する組織化学的研究. 肩関節21, 1997 (印刷中)

• 6) 和田元, 加藤哲也: 前関節症から股関節症の病勢進展について, 変形性股関節症 (整形外科MOOK 7), pp1-11, 金原出版, 東京, 1979

• 7) Klaue L, Durnin CW, Ganz R: The acetabular rim syndrome: a clinical presentation of dysplasia of the hip. J Bone Joint Surg 73-B: 423 429, 1991

• 8) 穂苅行貴, 井手隆俊, 井上肇ら:股関節唇障害の分類と治療について. 整形外科47: 553-556, 1996

• 9) 扇谷浩文: 関節鏡所見からみた変形性股関節症の病勢進展, 日整会誌68: 125-138, 1994

• 10) Harris WH, Bourne RB, Oh I: Intra-articular acetabular labrum: a possible etiological factor in certain cases of osteoarthritis of the hip. J Bone Joint Surg 61 A: 510-514, 1979

• 11) 扇谷浩文, 黒木良克: 関節造影法. 図説整形外科診断治療講座16 (宇田川英一編), pp18-27, 東京, メジカルビュー社, 1991

• 12) 櫛田和義, 永田正博, 高尾良英ら: 前股関節症の病勢進展-関節唇の損傷とSharp角, CE角の関連, Hip Joint 12: 209-212, 1986

• 13) Czerny C, Hoffmann S, Neuhold A, et al: Lesions of the acetabular labrum: accuracy of MR imaging and MR arthrography in detection and staging. Radiology 200: 225-230, 1996

• 14) Hasegawa Y, Fukatsu H, Matsuda T, et al: Magnetic resonance imaging in osteoarthritis of the dysplastic hip. Arch Orthop Trauma Surg 115: 243-248, 1996
  pubmed

• 15) 久保俊一, 赤木祥範, 堀井基行ら: 変形性股関節症における寛骨臼関節唇-放射状MRIによる観察. Hip Joint 22: 107-113, 1996

• 16) 堀井基行, 久保俊一, 赤木祥範ら: 放射状MRIによる健常寛骨臼関節唇の画像所見, 整形外科48: 8-13, 1997

• 17) 久保俊一, 堀井基行, 赤木祥範ら: 臼蓋形成不全症における寛骨臼関節唇の異常とX線学的パラメーターとの関係: 放射状MRIを用いて. Hip Joint 23, 1997 (印刷中)

P.107 掲載の参考文献

• 1) Pettersson H, et al: MR imaging of the cervical spine in rheumatoid arthritis. AJNR 9: 573-577, 1988
  pubmed

• 2) Zygmunt S, et al: Reduction of rheumatoid periodontoid pannus following posterior occipitocervical fusion visualized by magnetic resonance imaging. Br J Neurosurg 2: 315-320, 1988

• 3) Sze G, et al: Pseudotumor of the craniovertebral junction associated with chronic subluxation: MR imaging studies. Radiology 161: 391-394, 1986
  pubmed

• 4) Crockard HA, et al: Damaged ligaments at the craniocervical junction presenting as extradural tumor: a differential diagnosis in the elderly. J Neurol Neurosurg Psychiat 54: 817-821, 1991

• 5) 吉田宗人ら: 環軸関節不安定症に伴う歯突起後方腫瘤の病態と治療. 臨整外30: 395-402, 1995

P.118 掲載の参考文献

• 1) Daly PA: Office management of osteoporosis: aguide for the primary care provider. Endocrinology 21: 565-574, 1995

• 2) Heaney RP: The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9: 1515-1523, 1994

• 3) deSouza AC, Nakamura T, Stergiopoulos K, et al: Calcium requirement in elderly Japanease women. Gerontology 37 (supp11): 43-47, 1991

• 4) 福本誠二: 骨粗鬆症療法の進歩. Ca補充の意義と効果. 内科75: 913-917, 1995

• 5) Orwoll ES, McClung MR, Oviatt SK, et al: Histomorphometric effects of calcium or calcium plus 25 (OH) Dtherapy in senile osteoporosis. J Bone Miner Res 4: 81-88, 1989
  pubmed

• 6) Ott SM: Bone density in adolescents. N Engl J Med 314: 1676-1686, 1986

• 7) 中村哲郎: 骨粗鬆症とカルシウム. 食品と開発26: 34-37, 1991

• 8) Walker ARP: The human requirement of calcium: shouled low intakes be supplemented? Am J Clin Nutr 25: 518-531, 1972

• 9) Stevenson JC, Whitehead MI, Padwick M, et al: Dietary intake of calcium and postmenopausal bone loss, Br Med J 297: 15-17, 1988

• 10) van Beresteijin ECH, van't Hof MA, de Waard H, et al: Relation of axial bone mass to habitual calcium intake and cortical bone loss in healthy early postmenopausal women. Bone 11: 7-13, 1990

• 11) Wickham CAC, Walsh K, Cooper C, et al: Dietary calcium, physical activity, and risk of hip fracture: a prospective study. Br Med J 299: 889-892, 1989

• 12) Nordin BEC: Osteomalacoa, osteoporosis and calcium deficiency. Clin Orthop 17: 235-238, 1960

• 13) Matkovic V, Kostial K, Simonovic I, et al: Bone status and fracture rates in two regions of Yugoslavia. Amer J Clin Nutr 32: 540-549, 1979
  pubmed

• 14) Holbrook TL, Barrett-Connor E; Calcium intake: convariates and confounders. Am J Clin Nutr 53: 741-774, 1991

• 15) Fujita T, Okamoto M, Tomita T, et al: Calcium metabolism in aging inhabitants of mountain verus seacoat communities in the Kii Peninsula. J Am Geriatrics Soc 25: 254-258, 1977

• 16) Kanis JA, Passmore R: Calcuim supplementation of the diet-I and II. Br Med J 298: 137-140; 205-208, 1989

• 17) Johnston CC, Miller JZ, Slemenda CW, et al: Calcium supplementation and increases in bone mineral density in children. New Engl J Med 327: 82-87, 1992
  pubmed

• 18) Lloyd T, Andon MB, Rollings N, et al: Calcium supplementation and bone mineral density in adocescent girls. JAMA 270: 841-844, 1993
  pubmed

• 19) Baran D, Sorensen A, Grimes J, et al: Dietary products for preventing vertebral bone loss in premenopausal women: a three-year prospective study. J Clin Endocrinol Metab 70: 264-270, 1990
  pubmed

• 20) Elders PJM, Netelenbos JC, Lips P, et al: Calcium supplemention reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55. J Clin Endocrinol Metab 73: 533-540, 1991

• 21) Riis B, Thomsen K, Christiansen C, et al: Does calcium supplemention prevent postmenopausal bone loss? A double-blind, contrlled clinical study. New Engl J Med 316: 173-177, 1987
  pubmed

• 22) Dawson-Hughes B, Dallal GE, Krall EA, et al: A controlled trial of the effect of calcium supplemention on bone density in postmenopausal women. New Engl J Med 323: 878-883, 1990

• 23) Aloia JF, Vaswani A, Yeh JK, et al: Calcium supplementation with and without hormonoe replacement therapy to prevent postmenopausal bone loss. Ann Inter Med 120: 97-103, 1994

• 24) Reid LR, Ames RW, Evans MC, et al: Effect of calcium supplementation on bone loss in postmenopausal women. New Engl J Med 328: 465-464, 1993

• 25) Reid LR, Ames RW, Evans MC, et al: Long-term effects of calcuim supplementation on bone loss and fractures in post menopausal women: a randomized controlled trial. Amer J Med 98: 331-335, 1995

• 26) Chapuy MC, Arlot ME, Duboeuf F, et al: Vitamin D 3 and calcium to prevent hip fractures in elderly women. New Engl J Med 327: 1637-1642, 1992
  pubmed

• 27) Lee CJ, Lawler CS, Johnson GH, et al: Effects of supplementation of the diets with calcium and calcuium-rich foods on bone density of elderly females with osteoporosis. Amer J Clin Nutr 34: 819-823, 1981

• 28) Ross PD, Davis JW, Epstein RS, et al: Preexisting fractures and bone mass predict vertebral fractures incidence in women. Ann Intern Med 114: 919-923, 1991
  pubmed

• 29) Chan GM: Dietary calcium and bone mineral status of children and adolescents. Am J Dis Child 145: 631-634, 1991
  pubmed

P.131 掲載の参考文献

• 1) ロバート・L・スウィージー, アネット・M・スウィージー (七川歡次監訳): 腰痛-その治療と予防法-, 東京, TBSブルタニカ, 1996

• 2) 厚生省大臣官房統計情報部保健社会統計課国民生活基礎調査室監修: グラフでみる世帯のあらまし-平成7年国民生活基礎調査の結果から-第4号, P16, 東京, 厚生統計協会, 1997

• 3) Spitzer WO (Chairman): Scientific approach to the assessment and management of activity-related spinal disorders. A monograph for clinicians. Spine 12 (7S), Europian edition, suppl 1, 1987

• 4) 西林保朗: 職業とリウマチ病. リウマチ病セミナーVII (七川歡次監修), pp112-128, 大阪, 永井書店, 1996

• 5) Silman AJ, Hochberg MC: Epidemiology of the rheumatic diseases. Oxford, Oxford University Press, 1993

• 6) 片岡治: 腰部脊柱管狭窄症の手術的治療-そのlateral spinal stenosis (脊柱管外側狭窄症) とfailed back surgery syndrome (腰椎手術失敗症候群) について-, リウマチ病セミナーII (七川歡次監修), pp 231-242, 大阪, 永井書店, 1991

• 7) Rothman RH, Simeone FA: Management of failures of lumbar disc surgery, In The Spine, Vol II (ed, Rothman RH, Simeone FA), pp506-509, Philadelphia, WB Saunders, 1975

• 8) Burton CV, Kirkaldy-Willis WH, Yong-Hing K, et al: Causes of failure of surgery on the lumbar spine. Clin Orthop 157: 191-199, 1981
  pubmed

• 9) 金田清志:腰部脊柱管狭窄症における術後成績不良例の病態と再手術. 整形外科Mook 41: 299-311, 1985

• 10) 武仲善孝: Undifferentiated Spondyloarthropathy. リウマチ病セミナーIII (七川歡次監修), pp36-44, 大阪, 永井書店, 1992

• 11) 西林保朗: 高齢者後彎の病態-新しい概念で捕らえるべき前屈症-, リウマチ病セミナーV (七川歡次監修), pp121-132, 大阪, 永井書店, 1994

• 12) Waddel G, Main CJ, Morris EW, et al: Chronic low-back pain, psychologic distress, and illness behavior, Spine 9: 209-213, 1984

• 13) Hasenbring M, Marienfeld G, Kuhlendahl D, et al: Risk factors of chronisity in lumbar disc patients. A prospective investigation of biologic, psychologic, and social predictors of therapy outcome. Spine 19: 2759-2765, 1994

• 14) 野口光一: 慢性痛と脊髄の神経ペプチド. ペインクリニック17: 365-374, 1996

• 15) 横田敏勝: 臨床医のための痛みのメカニズム (改訂第2版). 東京, 南江堂, 1997

• 16) Pountain GD, Keegan AL, Jayson MIV: Impaired fibrinolytic activity in defined chronic back pain syndromes, Spine 12: 83-86, 1987

• 17) Klimiuk PS, Pountain GD, Keegan AL, et al: Serial measurements of fibrinolytic activity in acute low back pain and sciatica. Spine 12: 925-928, 1987
  pubmed

• 18) Cooper RG, Mitchell WS, Illingworth KJ, et al: The role of epidural fibrosis and defective fibrinolysis in the persistence of postlaminectomy back pain, Spine 16: 1044-1048, 1991
  pubmed

• 19) Haaland AK, Graver V, Ljunggren AE, et al: Fibrinolytic activity as a predictor of the outcome of prolapsed intervertebral lumbar disc surgery with reference to background variables: results of a prospective cohort study. Spine 17: 1022-1027, 1992
  pubmed

• 20) 小瀬弘一: Enthesisの病態に関する研究-ジュバントラットの脊椎enthesis部病変について-. 日整会誌52: 649-662, 1978

• 21) 七川歡次, 武仲善孝, 西林保朗: enthesopathy. 季刊関節外科1: 247-253, 1982

• 22) 七川歡次, 武仲善孝, 西林保朗: 腰椎症-enthesopathy-. 関節外科9: 223-229, 1990

• 23) 西林保朗, 七川歡次, 福田眞輔ら: 根性腰痛症とEnthesopathy-椎間板ヘルニアにおけるEnthesisの電顕観察-. 日整会誌55: 1344-1345, 1981

• 24) Naylor A, Happey F, Turner RL, et al: Enzymic and immunological activity in the intervertebral disc. Orthop Clin North Am 6: 51-58, 1975
  pubmed

• 25) Elves MW, Bucknill T, Sullivan MF: In vitro inhibition of leucocyte migration in patients with intervertebral disc lesions. Orthop Clin North Am 6: 59-66, 1975
  pubmed

• 26) Gertzbein SD, Tile M, Gross A, et al: Autoimmunity in degenerative disc disease of the lumbar spine. Orthop Clin North Am 6: 67-74, 1975
  pubmed

• 27) Takenaka Y, Kahan A, Amor B: Experimental autoimmune spondylodiscitis in rats. J Rheumatol 13: 397-400, 1986
  pubmed

• 28) Tolonen J, Gronblad M, Virri J, et al: Basic fibroblast growth factor immunoreactivity in blood vessels and cells of disc herniations. Spine 20: 271-276, 1995
  pubmed

• 29) 南出晃人, 橋爪洋, 林信宏ら: basic FGFが遊離脱出椎間板の消退過程に及ぼす影響について. 日整会誌71: S1676, 1997

• 30) 佐藤靖史編: 血管新生学, 東京, メディカルレビュー社, 1997

• 31) 松尾理編: 線溶系の新展開-細胞機能に関与する線溶系因子の役割-. 東京, 学際企画, 1992

• 32) 東城博雅: ホスホリパーゼA, と炎症. リウマチ病セミナーV (七川歡次監修), pp193-202, 大阪, 永井書店, 1994

• 33) Saal JS: The role of inflammation in lumbar pain. Spine 20: 1821-1827, 1995

• 34) 福田眞輔: 腰痛と生物活性物質. リウマチ病セミナーVII (七川歡次監修), pp99-105, 大阪, 永井書店, 1996

• 35) Deyo RA, Bass JE: Life style and low-back pain. The influence of smoking and obesity. Spine 14: 501-506, 1989
  pubmed

• 36) Hoyland JA, Freemont AJ, Jayson MIV: Intervertebral foramen venous obstruction. A cause of periradicular fibrosis? Spine 14: 558-568, 1989

• 37) Rydevik BL, Myers RR, Powell HC: Pressure increase in the dorsal root ganglion following mechanical compression. Closed compartment syndrome in nerve root. Spine 14: 574-576, 1989
  pubmed

• 38) Wheeler AH, Hanley EN: Spine update, Nonoperative treatment for low back pain. Rest to restoration. Spine 20: 375-378, 1995

• 39) Shea DD, Ohnmeiss DD, Smith WJ, et al: The effect of sensory deprivation in the reduction of pain in patients with chronic low-back pain. Spine 16: 560-561, 1991

• 40) Takemasa R, Yamamoto H, Tani T: Trunk muscle strength in and effect of trunk muscle exercises for patients with chronic low back pain. The differences in patients with and without organic lumbar lesions. Spine 20: 2522-2530, 1995
  pubmed

• 41) Moffett JAK, Chase SM, Portek I, et al: A controlled, prospective study to evaluate the effectiveness of a back school in the relief of chronic low back pain. Spine 11: 120-122, 1986

• 42) Werneke MW, Harris DE, Lichter RL: Clinical effectiveness of behabioral signs for screening chronic low-back pain patients in work-oriented physical rehabilitation program. Spine 18: 2412-2418, 1993

• 43) Watkins RG, O'Brien JP, Draugelis R, et al: Comparisons of preoperative and postoperative MMPI data in chronic back patients. Spine 11: 385-390, 1986
  pubmed

• 44)Triano JJ, McGregor M, Hondras MA, et al: Manipulative therapy versus education programs inchronic low back pain. Spine 20: 948-955, 1995

• 45) Augustinsson LE, Sullivan L, Sullivan M: Physical, pshchologic, and social function in chronicpain patients after epidural spinal electrical stimulation. Spine 11: 111-119, 1986

• 46) Ward NG: Tricyclic antidepressants for chronic low-back pain. Mechanisms of action and predictors of response. Spine 11: 661-665, 1986
  pubmed

• 47) Sihvonen T, Herno A, Paljarvi, et al: Local denervation atrophy of paraspinal muscles in postoperative failed back syndrome. Spine 18: 575-581, 1993
  pubmed

• 48) 中野正人, 松井寿夫, 三秋謙太郎ら: ラット腰椎後方侵襲後の馬尾変性とその抑制. 日整会誌71: S1666, 1997

• 49) Belch JJF, Madhok R, McArdle B, et al: The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of Stanozolol. Q J Med 58: 19-27, 1986

• 50) Jarrett PE, Morland M, Browse NL: Treatment of Raynaud's phenomenon by fibrinolytic enhansement. Br Med J 2: 523-525, 1978
  pubmed

• 51) Browse NL: Venous ulceration. Br Med J 286: 1920-1922, 1983

• 52) Grahame R, Clark B, Watson M, et al: Toward a rational therapeutic strategy for arachnoiditis. A possible role for d-penicillamine, Spine 16: 172-175, 1991

• 53) Langenskiold A, Valle M: Epidurally placed free fat grafts visualized by CT scanning 15-18 years after discectomy. Spine 10: 97-98, 1985
  pubmed

• 54) Henderson R, Weir B, Davis L, et al: Attempted experimental modification of postlaminectmy membrane by local instillation of recombinant tissue-plasminogen activator gel. Spine 18: 1268-1272, 1993
  pubmed

• 55) Abitbol JJ, Lincoln TL, Lind BI, et al: Preventing postlaminectomy adhesion. A new experimental model. Sping 19: 1809-1814, 1994

• 56) Onge RS, Weiss C, Denlinger JL, et al: A preliminary assessment of Na-hyaluronate injection into " no man's land" for primary flexor tendon repair. Clin Orthop 146: 269-275, 1980

• 57) Medina M, Paddock HN, Connoly RJ, et al: Novel antiadhesion barrier does not prevent anastomic healing in rabbit model. J Invest Surg 8: 179-186, 1995

• 58) Miller JA, Ferguson RL, Powers DL, el al: Efficacy of hyaluronic acid/non steroidal anti inflammatory drug systems in preventing tendo adhesions. J Biomed Mater Res (Appl Biomater) 38: 25-33,1997

検査法

P.142 掲載の参考文献

• 1) Silman AJ: The patient with fracture. The risk of subsequent fractures. Am J Med 98: 2A12-16, 1995

• 2) Nevitt MC, Johnell O, Black DM, et al: Bone mineral density predicts non-spine fractures in very elderly women. Osteoporosis Int 4: 325-331, 1994

• 3) Cumrnings SR, Black DM, Nevitt MC, et al: Bone density at various sites for prediction of hip fractures. The Lancet 341: 72-75, 1993

• 4) Faulkner KG, Cumming SR, Black D, et al: Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. J Bone Min Res 8: 1211-1217, 1993

• 5) Dargent-Molina P, Favier F, Grandjean H, et al: Fall-related factors and risk of hip fractre: the EPIDOS prospective study. The Lancet 348: 145-149, 1996

• 6) Hayes WC, Myers ER, Morris JN, et al: Impact near the hip dominates fracture risk in elderly nursing home residents who fall. Calcif Tissue Int 52: 192-198, 1993
  pubmed

• 7) Greenspan SL, Myers ER, Maitkand LA, et al: Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 271: 128-133, 1994

• 8) Akesson K, Vergnaud P, Gineyts E, et al: Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 53: 162-169, 1993
  pubmed

• 9) Hodges SJ, Akesson K, Vergaud P, et al: Circulating levels of vitamins KI and K2 decreased in elderly women with hip fracture. J Bone Min Res 8: 1241, 1993

• 10) Garnero P, Hausherr E, Chapuy MC, et al: Markers of bone resorption predict hip fracture in elderly wornen: the EPIDOS prospective study. J BoneMin Res 11: 1531-1538, 1996

• 11) Szulc P, Chapuy MC, Meunier PJ, et al: Serum undercalboxylated osteocalcin is a marker of the ris of hip fracture in elderly women. J Clin Invest 91: 1769-1774, 1993

• 12) Pack M, Constantinou DC, Kalia K, et al: Substitution of serine for α1 (I) glycine 844 in a severe variant of osteogenesis imperfecta minimally destabilized the triple helix of type I procollagen. J Biol Chem 264: 19694-19699, 1989

• 13) Spolita LD, Constantinou CD, Serda L, et al: Mutation in a gene for type I procollagen (COL1A2) in a women with postrnenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis miperfecta. Proc Natl Acad Sci 88: 5423-5427, 1991

• 14) Bailey AJ, Wotton SF, Sims TJ, et al;Post-translational modifications in the collagen of human osteoporotic femoral head. Biochem Biophys Res Com 185: 801-805, 1992
  pubmed

• 15) Kowitz J, Knippel M, Schuhr T, et al: Alteration in the extent of collagen l hydroxylation, isolated from femoral heads of women with a femoral neck fracture caused by osteoporosis. Calcif Tissue Int 60: 501 505, 1997

P.149 掲載の参考文献

• 1) Pincus T, Stein CM: What is the best source of useful data on the treatment of rheumatoid arthritis. Clinical trials, clinical observation, or clinieal protocols? J Rheumatol 22: 1611-1617, 1995
  pubmed

• 2) Boers M: The validity of radiography as an outcome measure in rheumatoid arthritis. J Rheumatol 22: 1783-1786, 1995
  pubmed

• 3) Steinbrocker O, Traeger CH, Battman RC: Therapeutic criteria in rheumatoid arthritis, JAMA 140: 659-665, 1949

• 4) Kellgren JH, Bier F: Radiological sign in rheumatoid arthritis: astudy of observed differences in the reading of hand films. Ann Rheum Dis 15: 1555-1560, 1956

• 5) Berns DL, Lin RK: Roentgen diagnosis of rheumatoid arthritis. Springfield, ILCC Thmas, 1969

• 6) Sharp JT, Young DY, Bluhm GB, et al: How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis. Arthritis Rheum 28: 1326-1335, 1985

• 7) Sharp JT, Lidsky MD, Collins LC: Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 14: 706-720, 1971
  pubmed

• 8) Larsen A, Dale K, Eek M: Radiographic evaluation of rheumatoid arthritis and related condition by standard reference films. Acta Radiol 18: 481-491, 1971

• 9) Trentham DE, Masi AT: Carpo: metacarpal ratio: Anew quantitative measure of radiologic progression of wrist involvement in rheumatoid arthritis. Arthritis Rheum 19: 939-944, 1976

• 10) van der Heide A, Remme CA, Hoffman DM, et al: Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 38: 1466-1475, 1995

• 11) Amos RS, Constable JT, Crocker DR, et al: Rheumatoid arthritis;relation of serum Creactive protein and erythrocyte sedimentation rate to radiographic changes. Brit Med J 1: 195-197, 1977

• 12) 前田晃: X線像の評価法, 免疫調節剤の薬効評価法, 日本リウマチ協会薬効検定委員会, pp95-97, 永井書店, 大阪, 1985

• 13) 東 威: 慢性関節リウマチのX線写真評価, 免疫調整剤の薬効評価法, 日本リウマチ協会薬効検定委員会, pp98-100, 永井書店, 大阪, 1985

• 14) 林 泰史, 吉田耕志郎, 向井英一: 手指関節病変のX線写真による評価, 薬効評価の新しい展開, 日本リウマチ財団薬効検定委員会, pp16-21, 医科学出版社, 東京, 1993

• 15) 市川陽一, 篠沢妙子: RAの関節X線写真読影値の変動, 薬効評価の新しい展開, 日本リウマチ財団薬効検定委員会, pp23-29, 医科学出版社, 1993

• 16) 宗圓 聡, 田中清介: RA患者に対する薬物療法のX線学的評価と臨床評価, 薬効評価の新しい展開, 日本リウマチ財団薬効検定委員会, pp30-35, 医科学出版社, 東京, 1993

• 17) 藤森十朗, 吉野慎一: 抗リウマチ剤の骨軟骨破壊抑制効果 (X線学的評価からの検討). 薬効評価の新しい展開, 日本リウマチ財団薬効検定委員会, pp36-41, 医科学出版社, 東京, 1993

• 18) 七川歓次, 広田茂永: 非侵食性RA, リウマチ病セミナーIV (七川歓次監修), pp30-37, 永井書店, 大阪, 1993

• 19) van der Heide DMFM, van Leewen MA, van RIEL LCM, et al: Biannual radiographic assessmentof hands and feet in a three year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 35: 26-34, 1992

• 20) Lopez-Mendez A, Daniel WH, Readug JC, et al: Radiographic assessment of disease progression inrheumatoid arthritis patients enrolled in the cooperative symptomatic studies of the rheumatic diseases program randomized clinical trial of MTX, Auranofin or a combination of the two. ArthritisRheum 36: 1364-1369, 1993

• 21) Laan AFJM, van Riel PLCM, Haagsme CT, et al: Divergent clinical and radiographic responses tolow dose prednisone in rheumatoid arthritis. Arthritis Rheum (suppl) 36: S214, 1993

• 22) Plant MJ, Saklatvela J, Borg AA, et al: Measurement and prediction of radiological progression inearly rheumatoid arthritis. J Rheumatol 24: 1808-1813, 1994

• 23) Wilkens RF, Sharp JT, Stablein D, et al: Comparisson of cyathioparin, methotrexate and the combination of the two in the treatment of rheumatoid arthritis. Arthritis Rheum 38: 1799-1806, 1995

• 24) Paimela L: The radiographid criterion in the 1987 revised criteria for rheumatoid arthritis: reassessment in a prospective study of early disease. Arthritis Rheuln 35: 255-258, 1992

• 25) Forre O: Radiologic evidence of disease modification in rheurnatoid arthritis patients treated with cyclosporine. Arthritis Rheum 37: 1506, 1512, 1994

• 26) Mottenen T, Paimela L, Ahonen J, et al: 0utcome in patients with early rheumatoid arthritistreated according to the"Sawtooth"strategy. Arthritis Rheum 39: 996-1005, 1996

• 27) Pasero G, Priolo F, Marnhini E, et al: Slow progression of joint damage in rheumatoid arthritistreated with cyclosporin A. Arthritis Rheum 39:1006-1015, 1996

• 28) 村田紀和, 前田 晃: 早期RAの手足の変形予防に対する長期臨床研究: 手のレ線変化とHLA. DR 4.1 との相関, 平成5年度大阪府特定疾患調査研究結果報告書, 骨, pp77〜81, 1993

• 29) Brook A, Corbett M: Radiographic changes in early rheumatoid arthritis. Ann Rheum Dis 36: 71-73, 1977
  pubmed

• 30) Mireno I, Valenzala A, Garcia A, et al: Association of the shared epitope with radiological severityof rheumatoid arthritis. J Reumatol 234: 6-9, 1996

• 31) Arnason JA, Jonsson T, Breckan A, et al: Relation between bone erosion and rheumatoid factorisotopes. Ann Rheum Dis 46: 380-384, 1987

• 32) Grindulus KA, Scott DL, Struthers GR: The measurement of radiological changes in the hands andwrists in rheumatoid arthritis. Rheumatol Int 3: 39-42, 1983

• 33) Fries JS, Bloch DA, Sharp JT, et al: Assessment of radiologic progression in rheumatiod arthritis. Arthritis Rheum 29: 1-9, 1986

• 34) Cuchacowich M, Couret M, Peray P, et al: Precision of the Larsen and the Sharp methods of assessing radiologic change in patients with rheumatoid arthritis. Arthritis Rheum 35: 736-739, 1992

• 35) Sharp JT, Wolfe F, Williams GP, et al: Radiological progression in rheumatoid artiritis: howmany patients are required in a treatment trial to test disease rnodification? Ann Rheum Dis 52: 332-337, 1993

• 36) Nance EP, Kage JJ, Callahan FE, et al: Observer variation in quantitative assessment of rheumatoid arthritis. Invest Radiol 21: 922.-927, 1986

• 37) Wassemberg S, Herborn G, Fischer S, et al: Comparisson of Larsen: s and Sharp: smethod of scoringradiographs in rheumatoid arthritis. Arthritis Rheum (suppl) 37: S. 250, 1994

• 38) Norgaad F: Earliest roentgenological changes in polyarthritis of the rheumatoid type. Radiology85: 325-329, 1965

• 39) Brewenton PA: Atangential radiographic projection for demonstrating involvement of metocanpalheads in rheumatoid arthritis. Br J Radiol 40: 233-244, 1967
  pubmed

• 40) Higgs JB, Smith D, Rosier KF, et al: Quantitative measurement of erosion growth and joint sPaceloss in rheumatoid arthritis hand radiographs. J Rheumatol 23: 265-272, 1996

• 41) Cush JJ, Erdman WA, Jayson HT, et al: Magnetic resonance imaging in the evalution of inflammatory and erosive changes in early rheumatoid arthritis. Arthritis Rheum (suppl) 34: S64, 1992

• 42) Eng BJ, Hollister AM, Weil J, et al: Use of MRI with 3-dimensional reconstraction to measure changes in the synovium and joint in rheumatoid arthritis. Arthritis Rheum (suppl) 35: S196, 1992

• 43) Plant MJ, Stwart WR, Williams GP, et al: Gadolium-enhanced magnetic resonance imaging of the finger joints in rheumatoid arthritis. Brit J Rheumatol 226: 118, 1996

• 44) Yeap SS, Hassen WV, Ray S, et al: Hand MRI changes in early rheumatoid arthritis. Brit J Rheumatol 226: 118, 1996

• 45) Devlin V, Gough A, Lily J, et al: High loss of bone mass documented in hands of patients with early rheumatoid arthritis. Arthritis Rheum (suppl) 36: S214, 1993

• 46) Deodhor AA, Davis MJ, Woolf AD: Monitoring rheumatoid arthritis by hand bone densitometry. Arthritis Rheum (supply) 36: S214, 1993

• 47) Gaydecki PA, Browne M, Mamtow H, et al;Measurement of radiographic changes occuring in rheumatoid arthritis by image analysis technisques. Ann Rheum Dis 46: 291-296, 1987

• 48) Allander E, Forogren PO, Pettersson H, et al: Computerized assessment of radiological changes of the hand in rheumatic disease. Scand J Rheumatol 18: 291-296, 1989

• 49) Moreland LW, Reddy MS, Koopman WH, et al: Digital substraction radiography for the assessment of bone changes in rheumatiid arthritis. J Rheumatol 19: 697-703, 1992

• 50) James MF, Heald G, Shorter JH, et al: Joint space measurement in hand radiographs. Arthritis Rheum 38: 891-901. 1995
  pubmed

• 51) James MF, Byme J, Heald G, et al: Radiographic joint space assessrnent: scoring computed with digital image analysis. Arthritis Rheum (suppl) 36: S214, 1993

• 52) Byme J, Gough, Dacre JE, et al: Detection of radiographic joint space loss using digital image analysis in early rheumatoid arthritis. Arthritis Rheum (suppl) 36: S214, 1993

• 53) Budkland-Wright JC, Carmlichael I, walker SR: Quantitative microfocal radiography accurately detects joint changes in rheumatoid arthritis. Ann Rheum Dis 45: 379. 383, 1985

• 54) Budkland-wright JC, C (arke GS, Chikanza IC, et al: Qunatitative microfocal radiography detects changes in erosion area in patients with rheumatoid arthritis treated with myocrisin. J Rheumatol 20: 203-207, 1993

生物学的反応

P.162 掲載の参考文献

• 1) Wekerle H, Ketelsen U-P: Thymic nurse cells-Ia-bearing epithelium involved in T-lymphocyte defferentiation? Nature 283: 402. 404, 1980

• 2) Wekerle H, Ketelsen U-P, Ernst, M: Thymic nurse cells. Lymphoepithelial cell complexes in murine thymus: morphological and serological characterization. J Exp Med 151: 925-944, 1980
  pubmed

• 3) Boyd RL, Tucek CL, Godfrey DI, et al: The thymic microenvironment, Immunol Today 14: 445-459, 1993
  pubmed

• 4) Penninger J, Wick G: Thymic nurse cell lymphocytes react against self major histocompatibility complex. Eur J Immunol 22: 79-83, 1992
  pubmed

• 5) Rieker T, Penninger J, Hala K, et al: In situ analyses of in ovo graft-vs.-host reaction induced by thymic nurse cell lymphocytes. Eur J Immunol 23: 904-910, 1993
  pubmed

• 6) Nakagawa S, Hata M, Seki M, et al: Interaction of cutaneous stromal cells and γ/δTcell receptor (TcR)-positive cells. 1. Vγ-γ/δ TcR+Tcells migrating from organ-cultured murine skin proliferateby co-culture with cutaneous stromal cells in the presence of interleukin-2. Eur J Immunol 23: 1705-1710, 1993

• 7) Iwagami S, Furue S, Toyosaki T, et al: Establishment and characterization of nurse ce11-like clones from human skin: nurse cell like clones can stimulate autologous mixed lymphocyte reaction. J Immunol 153: 2927-2938, 1994

• 8) Tanabe M, Ochi T, Tomita T, et al: Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol 21: 830-835, 1994
  pubmed

• 9) Tang J, Scott G, Ryan DH: Subpopulations of bone marrow fibroblasts support VLA-4-mediated migration of B-cell precursors. Blood 82: 3415-3423, 1993
  pubmed

• 10) 鈴木隆二, 豊崎朋子, 鶴田裕次ら: RA患部に見出されたナース細胞の性状と病態との関連性. 平成6年度厚生省リウマチ調査研究事業研究報告書, p131, 厚生省, 1995

• 11) 冨田哲也, 越智隆弘, 島岡康則ら: 慢性関節リウマチと骨髄-慢性関節リウマチ患者の全身性病態として認められる異常な骨髄球系細胞-. 日整会誌 67: S1226, 1993
  Medical*Online

• 12) 冨田哲也, 越智隆弘, 島岡康則ら: 慢性関節リウマチと骨髄 (2) 骨髄球系細胞の分化機序. 日整会誌66: S1288, 1992

• 13) 越智隆弘, 冨田哲也ら: 骨髄の研究病態解明に関する研究班, 平成4年度厚生省リウマチ調査研究事業総合研究報告書, 厚生省, pp77-80, 1993

• 14) 冨田哲也, 越智隆弘, 鈴木隆二ら: 重症慢性関節リウマチ患者骨髄, 滑膜由来ナース様細胞膜抗原異常な骨髄球系細胞の分化, 維持機能. 日整会誌 68: S1299, 1994

• 15) 冨田哲也, 島岡康則, 越智隆弘ら: RA骨髄に認められる細胞組成の変化. 炎症と免疫, pp629-636, 1994

• 16) Kaisho T, Oritani K, Ishikawa J, et al: Human bone marrow stromal cell lines from myeloma and rheumatoid arthritis that can support murine pre-B cel1 growth. J Immuno1149: 4088-4095, 1992

• 17) Kaisho T, Ishikawa J, Oritani K, et al: BST-1, a novel surface molecule of bone marrow stromal cel1 1ines that facilitates pre-B cell growth. Proc Natl Acad Sci USA 91: 5325-5329, 1994

• 18) 石川 淳, 石原克彦, 平野俊夫: RA骨髄由来の間質細胞によるプレB細胞増殖維持機構.炎症と免疫 2: 637-642, 1994

• 19) Jannosy G, Panayi GS, Duke O, et al: Rheumatoid arthritis: a disease of T-lymphocyte/macro-phage immunoregulation. Lancet 2: 839-942, 1981

• 20) Toyosaki T, Tsuruta Y, Yoshioka T, et al: Recognition of synovial cell antigen by CD4+CD8-T cell clones established from rheumatoid arthritis patients. Arhtiritis Rheum 39: S266, 1996

• 21) Thomas R, Davis S, Lipsky PE: Rheumatoid synovium is enriched in mature antigen-presenting cells. J Immunol 152: 2613-2623, 1995

• 22) Shroder AE, Greiner A, Seyfect C, et al: Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 93: 221-225, 1996

• 23) 鈴木隆二, 豊崎朋子: 慢性関節リウマチにおける滑膜および骨髄ナース細胞とこれらに特異的なTおよびB細胞に関する研究. 平成8年度厚生省長期慢性疾患総合研究事業研究報告書, pp109-111, 厚生省, 1997

• 24) Salmon M, Scheel-Toellner D, Huissoon AP, et al: Inhibition of T cell apoptosis in rheumatoid synovium. J Clin Invest 99: 439-446, 1997
  pubmed

• 25) Ochi T, Iwase R, Yonemasu K, et al: Natural course of jouint destruction and fluctuation of serurn C1q levels in patients with rheumatoid arthritis. Arthritis Rheum 31: 37-43, 1988

• 26) Ochi T, Yonemasu K, Iwase R, et al: Serum Clq levels as a prognostic guide to articular erosions in patients with rheumatoid arthritis. Arthritis Rheum 27: 883-887, 1994

P.168 掲載の参考文献

• 1) Risdall RJ, McKenna RW, Nesbit ME, et al: Virus-associated hemophagocytic syndrome. A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 44: 993-1002, 1979
  pubmed

• 2) Starkie CM, Kenny MW, Mann JR, et al: Histiocytic medulary reticulosis following acute lymphoblastic leukemia. Cancer 47: 537-544, 1981

• 3) Sullivan JL, Woda BA, Herrod HG, et al: Epstein-Barr virus associated hemophagocytic syndrome: virological and immunopathological studies. Blood 65: 1097-1104, 1985
  pubmed

• 4) Wong KF, Hui PK, Chan JKC, et al: The acute lupus hemophagocytic syndrome. Ann Intern Med 114: 387-390, 1991

• 5) Wong KF, Chan JKC: Reactive hemophagocytic syndrome. a clinicopathologic study of 40 patients in an oriental population, Am J Med 93: 177-180, 1992

• 6) Falini B, Pileri S, De Solas I, et al: Peripheral T-cell lymphoma associated with hemophagocyic syndrome. Blood 75: 434-444, 1990

• 7) 河 敬世: 血液悪性腫瘍と血球貧食症候群. 医学のあゆみ177: 673-676, 1996

• 8) 生島 聡, 江角典子, 嶺 宏ら: Malignant histiocytosis/virus associated hemophagocytic syndromeにおける血清フェリチン測定の意義.臨床血液29: 589-595, 1988

• 9) 野村昌作, 越川佳代子, 濱本健次郎ら: ステロイドとγ-グロブリンの併用が著効を示したvirus associated hemophagocytic syndromeの1例. 臨床血液33: 1242-1247, 1992

• 10) Komp DN, McNamara J, Buckley P: Elevated soluble interleukin-2 receptor in childhoo hemophagocytic histiocytic syndrome. Blood 73: 2128-2132, 1989

• 11) 中瀬 勉, 森田孝一, 留奥 誠ら: 成人発症Hemophagocytic syndromeの2例. 臨床血液31: 248-259, 1990

• 12) 幸田久平, 望月智博, 松本修二ら: γ-グロブリン大量投与が著効した高齢者virus-associated hemophagocytic syndrome (VAHS)の1例. 日本内科学会雑誌85: 763-764, 1996

• 13) Reinier AP, Spivak JL: Hematophagic histiocytosis. Medicine 67: 369-388, 1988

• 14) Prieur AM, Stephan JL: Macrophage activation syndrome in children with joint diseases. Rev Rhum (Engl Ed) 61: 385-388, 1994

• 15) Coffernils M, Soupart A, Pradier O, et al: Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndrome. J Rheumatol 19: 1425-1427, 1992

• 16) 熊倉俊一, 石倉浩人, 小林祥泰ら: 自己免疫関連血球倉食症候群.医学のあゆみ177: 683-689, 1996

P.173 掲載の参考文献

• 1) Van Boxel JA, Paget SA: Predominantly T-cell infiltrate in rheulnatoid synovial membrane. N Engl J Med 293: 517-520, 1975
  pubmed

• 2) Monsmann TR, Cherwinski H, Bond MW, et al: Two types of murine helper Tcell clone. I. Identification according to profiles of lymphokine activities and secreted proteins. J Immuno1136: 2348-2357, 1986

• 3) Del Prete GF, De Carli M, Ricci M, et al: Helper activity for immunoglobulin synthesis of T helper type (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J Exp Med 174: 809-813, 1991

• 4) Cher DJ, Mosmann TR;Two types of murine helper T cell clone. II. Delayed-type hypersensitivityis mediated by TH1 clones. J Immunol 138: 3688-3694, 1987

• 5) Del Prete GF, De Carli M, Mastromauro C, et al: Purified protein derivative of Mycobacterium tuberculosis and excretory-sectetory antigen (s) of toxocara canis expand in vitro human T cells withstable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest88: 346-350, 1991

• 6) Ogawa T, Uchida H, Yasuda K: Mapping of murine Th1 and Th2 helper T-cell epitopes on finbriae from Porphyromonas gingivalis. J Med Microbiol 42: 165-170, 1995

• 7) Suzuki J, isobe M, Sekiguchi M, et al: Cytokine expression in cardiac allograft in mice with peripheral tolerance induced by anti-ICAM-1 and anti-LFA-1 monoclonal antibodies. Transplant Proc 27: 370-371, 1995
  pubmed

• 8) Naito Y, Endo H, Arai K, et al: Signal transduction in Th clones: target of differential modulation by PGE2 may reside downstream of the PKC-dependent pathway. Cytokine 8: 346-356, 1996
  pubmed

• 9) Trembleau S, Penna G, Bosi E, et al. Interleukin 12 administration induces T helper type 1 cells andaccelerates autoimmune diabetes in NOD mice. J Exp Med 181: 817-821, 1995
  pubmed

• 10) Kennedy MK, Torrance DS, Picha KS, et al: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149: 2496-2505, 1992

• 11) Shulze-Koops H, Lipsky PE, Kavanaugh AF, et al: Elevated Th1-or Th 0-like cytokine mRNA inperipheral circulation of patients with rheumatoid arthritis. J Immunol 155: 5029-5037, 1995

• 12) Simmon AK, Seiplet E, Sieper J: Divergent T-cell cytokine patterns in inflammatory arthritis. ProcNatl Acad Sci USA 91: 8562-8566, 1994

• 13) Cush JJ, Splawski JB, Thomas R, et al: Elevated interleukin-10 levels in patients with rheumatoidarthritis. Arthritis Rheum 38: 96-104, 1995

• 14) Llorente L, Richaud-Patin Y, Fior R, et al: In vivo production of interleukin-10 by non-T cels in rheumatoid arthritis, Shogren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactirity and autoimmunity. Arthritis Rheum 37: 1647-1655, 1994

• 15) Thomson CB: Distinct roles for the costimulatory ligands 137. 1 and B7-2 in T helper celldiferentiation?Ceh 81: 979-982, 1995

• 16) Miossec P: Propri6t6s anti-inflammatoires de I'interleukine 4. Rev Rheum 60: 119-124, 1993

• 17) Schlaak J, Hermann E, Ringhoffer M, et al: Predominance of Th1-type T cell in synovial fluid of patients with Yersinia-induced reactive arthrits. Eur J Immunol 22: 2771-2776, 1992

• 18) Kelso A: Th1 and Th2 subsets: paradigms lost?Immunology Today 16: 374-379, 1995
  pubmed

• 19) Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today 17: 138-146, 1996
  pubmed

• 20) Chen Y, Kuchroo VK, Inobe JI, et al: Regulatory T cell clones induced by oral tolerance: suppression of auto-immune encephalomyelitis. Science 265: 1237-1240, 1994

P.178 掲載の参考文献

• 1) Nouri AME, Panayi GS, Goodman SM: Cytokines and the chronic inflammation of rheumatic diseases. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 55: 295-302, 1984

• 2) Wood DD, Ihrie EJ, Dinarello CA, et al: Isolation of an interleukin-1 1ike factor from human joint effusions. Arthritis Rheum 26: 975-983, 1983

• 3) Hopkins SJ, Humphreys M, Jayson MIV: Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-q. Clin Exp Immunol 72: 422-427, 1988

• 4) Westacott CI, Whicher JT, Barnes IC, et al: Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 49: 676-681, 1990
  pubmed

• 5) Holt I, Cooper RG, Denton J, et al: Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol 31: 725-733, 1992
  pubmed

• 6) Westacott CI, Taylor G, Atkins RM, et al: Interleukin-1α and β production by cells isolated from membrane around aseptically loose total joint replacements. Ann Rheum Dis 51: 638-642, 1992

• 7) Al Saffar N, Revell PA: Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implanats: Potential role in osteolysis. Br J Rheumatol 33: 309-316, 1994

• 8) Di Giovine FS, Nuki G, Duff GW: Tumor necrosis factor in synovial exudates. Ann Rheum Dis 47: 768-772, 1988
  pubmed

• 9) Hopkins SJ, Meager A: Cytokines in synovial fluid. The presence of tumor necrosis factor and inter-feron. Clin Exp Immunol 73: 88-92, 1988

• 10) Martel-Pelletier J, Cloutier JM, Pelletier JP: Cytokines, interleukin-1 and the tumor necrosis factor in human osteoarthritic tissue. Trans Orthop Res Soc 15: 111, 1990

• 11) Brennan FM, Chantry D, Jackson AM, et al: Cytokine production in culture by cells isolated from synovial membrane. J Autoimmun 28 (suppl): 177-186, 1992

• 12) Venn G, Nietfeld JJ, Duits AJ, et al: Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experunebtal canine osteoarthritis. Arthritis Rheum 36: 819-826, 1993
  pubmed

• 13) Westacott CI, Atkins RM, Dieppe PA, et al: Tumor necrosis factor-α receptor expression on chondrocytes isolated from human articular cartilage. J Rheumatol 21: 1710-1715, 1994

• 14) Denko CW, Boja B, Moskowitz RW: Growth promoting peptides in osteoarthritis: Insulin, IGF-I, growth hormone. J Rheumatol 17: 1217-1221, 1990
  pubmed

• 15) Denko CW, Boja B: Growth factor in asymptomatic osteoarthritis: insulin-like growth hormone. Immunopharmacology 2: 71-76, 1993

• 16) Middleton JFS, Tyler JA: Upregulation of IGF-I gene expression in the lesions of osteoarthritic human cartilage. Ann Rheum Dis 51: 440-447, 1992

• 17) Schouten JSAG, Van den Ouweland EA, Valkengurg HA, et al: insulin-like growth factor-I: Prognostic factor of knee osteoarthritis. Br J Rheumatol 32: 274-280, 1993

• 18) Dore S, Pelletier J-P, DeBattista JA, et al: Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor-I binding sites but are unresponsive to its stimulation: possible role of IGF-I binding proteins. Artiritis Rheurn 37: 253-263, 1994

• 19) Fava R, Olsen N, Keski-Oja J, et al: Active and latet forms of tranforming growth factor-β activity in synovial effusions. J Exp Med 169: 291-296, 1989

• 20) Ashton IK, Matheson JA: Change in response with age of human articular cartilage to plasma somatomedin activity. Calcif Tissue Int 29: 89-94, 1979
  pubmed

• 21) Recklies AD, Roughley PJ, Bilimoria KM: Differential response of young and old human articular chondrocytes to IGF-I and TGFβ. Trans Orthop Res Soc 14: 281, 1989

• 22) Curtis BM, Widmer MB, de Roos P, et al: IL-1 and its receptor are translocated to the nucleus. J Immunol 144: 1295-1303, 1990

• 23) Qwarnstrom EE, Page RC, Gillis S, et al: Binding, internalization, and intracellular localization of interleukin-1βin human diploid fibroblasts. J Biol Chem 263: 8261-8269, 1988

• 24) Martel-Pelletier J, McCollum R, DiBattista J, et al: The interlelukin-1 receptor in normal and osteoarthritic human articular chondrocytes: idenfication as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum 35: 530-540, 1992

• 25) Hutton CW, Higgs ER, Jacabson PC, et al: 99mTc HMDP bone scanning in generalised arthritis. II. The four hour bone scan image predicts radiographic change. Ann Rheum Dis 45: 622-626, 1986

• 26) Macfarlane DG, Buckland WJC, Emery P, et al: Comparison of clinical, radiounclide, and radiographic features of osteoarthritis of the hands. Ann Rheum Dis 50: 623-626, 1991

• 27) Dieppe P, Cushnaghan J, Young P, et al: Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 52: 557-563, 1993
  pubmed

• 28) Sokoloff L: Microcracks in the calcified layer of articular cartilage. Arch Pathol Lab Med 117: 191-195, 1993
  pubmed

• 29) Pelletier J-P, McCollum R, DiBattista J, et al: Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 36: 1517-1527, 1993
  pubmed

• 30) Franchi-Micheli S, Lavacchi L, Friedmann CA, et al: The influence of diacerhein on the biosynthesis of prostaglandin-like substances in vitro. J Pharm Pharmacol 35: 262-264, 1983

• 31) Petrillo M, Montrone F, Ardizzonw S, et al: Endoscopic evaluation of diacerhien-induced gastric mucosal lesions. Curr Ther Res 49: 10-15, 1991

• 32) Pujol JP: Collagenolytic enzymes and interleukin-1: their role in inflammation and cartilage degradation: the antagonistic effects of diacerhein on IL-1 action on cartilage matrix components. Osteoarthritis Cart 1: 82, 1993

• 33) Mazieres B, Berdah L: Effect of diacerhein (ART50) on an experimental post-contusive model of osteoarthritis. Osteoarthritis Cart 1: 47, 1993

• 34) Nguyen M, Dougados M, Berdah L, et al: Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 37: 529-536, 1994
  pubmed

• 35) Bandara G, Mueller GM, Galea-Lauri J, et al: Intraarticular expression of biologically active in terleukin-1-receptor-antagonist protein by ex vivo gene transter. Proc Natl Acad Sci USA 90: 10764-10768, 1993

• 36) Baragi VM, Renkiewidcz RR, Jordan H, et al: Transplantation of transduced chonrocytes protects articular catilage from interelukin 1-induced extracellular matrix degradation. J Clin Invest 96: 2454-2460, 1995

P.189 掲載の参考文献

• 1) Dabbagh AJ, Trenam CW, Morris CJ, et al: Iron in joint inflammation. Ann Rheum Dis 52: 67-73, 1993
  pubmed

• 2) Fillet G, Beguin Y, Baldelli L: Model of reticuloendothelial iron metabolism in humans: abnormal behaviour in idiopathic haemochromatosis and in inflammation. Blood 74: 844-851, 1989

• 3) Smith BJ, Speziale SC, Bowman BJ: Properties of interleukin-1 as a complete secretagogue for human neutrophils. Biochem Biophys Res Commun 130: 1233-1240, 1985

• 4) Higashi S, Ota T, Eto S: Biochemical analysis of ferritin subunits in sera from adult Still: s dsease patients. Rheumatol Int 15: 45-50, 1995

• 5) Konijn AM, Hershko C: Ferritin synthesis and inflammation. I. Pathogenesis of impaired iron release. Br J Haematol 37: 7-16, 1977
  pubmed

• 6) Williams RA, Samson D, Tikerpac J, et al: In vitro studies of ineffective erythropoiesis in rheumatoid arthritis. Ann Rheum Dis 41: 502507, 1982

• 7) Zarrabi MH, Lysik R, DiStefano J, et al: The anemia of chronic disorders: studies of iron reutilization in the anemia of experimental malignancy and chronic inflammation. Br J Haematol 35: 647-658, 1977.
  pubmed

• 8) Raja KB, Duane P, Snape SD, et al: In vitro duodenal iron uptake and serum and mucosal iron protein levels, with special reference to rheumatoid arthritis. Br J Rheumatol 3411041-1047, 1995

• 9) Baer AN, Dessypris EN, Goldwasser E, et al: Blunted erythropoietin response to anemia in rheuma toid arthritis. Br J Haematol 66: 559-564, 1987

• 10) Vreugdenhil G, Kroos MJ, Eijk HG, et al: Impaired iron uptake and transferrin binding by erythro blasts in the anemia of rheumatoid arthritis. Br J Rheumatol 29: 335-339, 1990

• 11) Mearns RT, Olsen NJ, Krantz SB, et al: Treatment of anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 32: 638-642, 1989

• 12) Dainiak N, Hardin J, Floyd V, et al: Humoral suppression of erythropoiesis in systemic lupus erythematosus. Am J Med 69: 537-544, 1980
  pubmed

• 13) Sugimoto M, Wakabayashi Y, Hirose S-1, et al l Immunological aspects of the anemia of rheumatoid arthritis. Am J Hematol 25: 1-11, 1987

• 14) Means RT, Dessypris EN, Krantz SB: Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 150: 59-64, 1992
  pubmed

• 15) Means RT, Dessypris EN, Krantz SB: Inhibition of human colony-forming units by tumor necrosis factor requires accessory cells. J Clin Invest 86: 538-541, 1990

• 16) Means RT, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647, 1992
  pubmed

• 17) Mamus SW, Beck-Schroeder S, Zanjani ED: Suppression of normal human erythropoiesis by gamma interferon in vitro: role of monocytes and T-lymphocytes, J Clin Invest 75: 1496-1503, 1985

• 18) Raefsky EL, Platanias LC, Zoumbos NC, et al: Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 135: 2507-2512, 1985
  pubmed

• 19) Vreugdenhil G, Lowenberg B, van Ejik HG, et al: Anaemia of chronic disease in rheumatoid arthritis: raised serum interleukin-6 (IL-6) levels and the effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int 10: 127-130, 1990

• 20) Feelders RA, Vreugdenhil JP, van Dijk AJG, et al: Decreased affinity and number of transferrin receptors on erythroblasts in the anemia of rheumatoid arthritis, Am J Hemato143: 200-204, 1993

• 21) Fleming D, Wood RJ: Plasma transferrin receptor helps to predict iron deficiency in the anemia of chronic disease. Nutrition Rev 53: 167-175, 1995
  pubmed

• 22) Houston T, Moore M, Porter D, et al: Abnormal haem biosynthesis in the chronic anaemia of rheumatoid arthritis. Ann Rheum Dis 53: 167-170, 1994
  pubmed

• 23) Kawasaki N, Tanimoto T, Tanaka A, et al: Determination of non-protein-bound iron in human synovial fluid by high-performance liquid chromatography with electrochemical detection. J Chromatography B 656: 436-440, 1994

• 24) Garty B, Kaminsky E, Moroz C: The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+lymphocytes. Clin Diagn Lab Immuno12: 225-226, 1995
  pubmed

• 25) Morikawa K, Oseko F, Morikawa S: H-and L-rich ferritins suppress antibody production, but not proliferation, of human B lymphocytes in vitro. Blood 83: 737-743, 1994
  pubmed

• 26) Golding S, Young SP: Iron requirements of human lymphocytes: relative contributions of intra and extra-cellular iron, Scand J Immunol 41: 229-236, 1995
  pubmed

• 27) Nishiya K: Stimulation of human synovial cell DNA synthesis by iron. J Rheumatol 21: 1802-1807, 1994
  pubmed

• 28) Blake DR, Bacon PA: Serum ferritin and rheumatoid disease. Br Med J 282: 1273-1981, 1981

• 29) Craft AW, Eastham EJ, Bell JI, et al: Serum ferritin in junenile chronic polyathritis. Ann Rheum Dis 36: 271-273, 1987

• 30) Van Reeth C, Le Moel G, Lane Y, et al: Serum Ferritins and isoferritins are tools for diagnosis of active still's disease. J Rheumatol 21: 890-895, 1994

• 31) 木村, 中西, 佐藤: SLEの血清フェリチン値. リウマチ24: 606, 1984

• 32) Cazzola M, Ponchio L, de Benedetti F, et al: Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87: 4824-4830, 1996
  pubmed

P.194 掲載の参考文献

• 1) Pietrogrande V: Osteopatia da prolungato trattamento cortisonico. Orthop Traumatol Protez 25. 791-810, 1957

• 2) Jones JP, Sakovlch L: Fat embolism of bone. A roentogenographic and histological investigation, with use of intra-arterial Lipiodol, in rabbits. J Bone Joint Surg 48-A: 149-164, 1966

• 3) Wang GJ, Sweet DE, Reger SI, et al: Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg 59-A: 729-735, 1977
  pubmed

• 4) Kawai K, Tarnaki A, Hirohata K: Steroid-induced accurnulation of lipid in the osteocytes of the rabbit femoral head: a histochemical and electron microscope study. J Bone and Joint Surg 67-A: 755-763, 1985

• 5) Hungerford DS: Pathogenetic considerations in ischemic necrosis of bone, Canad J Surg 24: 583-588, 1981
  pubmed

• 6) Warner JP, Philip JH, Brodsky GL, et al: Studies of nontraumatic osteonecrosis, Manometric andhistologic studies of the femoral head after chronic steroid treatment. An experimental study inrabbits, Clin Orthop 225: 128-140, 1987

• 7) Dubois CE, Cozen L: Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. J Am Med Assoc 174: 966-971, 1960

• 8) Siemsen JK, Brook J, Meister L: Lupus erythematosus and avascular bone necrosis. A clinical study of three cases and review of the literature. Arthritis Rheum 5: 492-501, 1962
  pubmed

• 9) Bergstein JM, Wiens C, Fish AJ, et al: Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr 85: 31-35, 1974
  pubmed

• 10) Rich AR, Gregory JE: The experimental demonstration that periarteritis nodosa is a manifestationof hypersensitivity. Bull Jones Hopkins Hosp 72: 65-88, 1943

• 11) Matsui M, Ohzono K, Nakamura N, et al: The immune reaction to heterologous serum causes osteonecrosis in rabbits. Virchows Arch 427: 205-211, 1995
  pubmed

• 12) Nakata K, Masuhara K, Nakamura N, et al: Inducible osteonecrosis in a rabbit serum sickness model: deposition of immune complexes in bone marrow. Bone 18: 609-615, 1996

• 13) 大園健二, 佐藤宗彦, 菅野伸彦: 特発性大腿骨頭壊死症における免疫グロブリンと自己抗体の意義. Hip Joint 21: 93-96, 1995

P.203 掲載の参考文献

• 1) Buckwalter J, Rosenberg L, Coutts R, et al: Articular cartilage: injury and repair. In Injury and Repair of the Musculoskeletal Soft Tissues, pp465-482. Park Ridge, Illinois, The American Academy of Orthopaedic Surgeons, 1987

• 2) Meachim G: The effect of scarification on articular cartilage in the rabbit. J Bone Joint Surg 45-B: 150-161, 1963

• 3) Fuller JA, Ghadially FN: Ultrastructural observations on surgically produced partial-thickness defects in articular cartilage, Clin Orthop 86: 193-205, 1972
  pubmed

• 4) Wakitani S, Goto T, Young RG, et al: Mesenchymal cell based repair of large full-thickness defects of articular cartilage. J Bone Joint Surg 76-A: 579-592, 1994
  pubmed

• 5) Furukawa T, Eyre DR, Koide S, et al: Biochemical study on repair cartilage resurfacing experimental defects in the rabbit knee. J Bone Joint Surg 62-A: 79-89, 1980

• 6) Wakitani S, Ono K, Caplan AI, et al: Repair of large cartilage defects in weight-bearing and semi-weight-bearing articular surfaces with allograft articular chondrocytes embedded in collagen gel. Orthopaedic Transaction 19: 437 438, 1994

• 7) Mitchell N, Shepard N: The resurfacing of adult rabbit articular cartilage by multiple perforations through the subchondral bone. J Bone joint Surg 58-A: 230-233, 1976

• 8) O'Driscoll SW, Keeley FW, Salter RB: The chondrogenic potential of free autogenous periosteal grafts for biological resurfacing of major full-thickness defects in joint surfaces under influence of continuous passive motion. An experimental investigation in the rabbit. J Bone Joint Surg 68-A: 1017-1035, 1986

• 9) Lexer E: Substitution of whole or half joints from freshly amputated extremities by free plastic operation. Surg Gynec Obstet 6: 601-607, 1908

• 10) Goldberg VM, Heiple KC: Experimantal hemijoint and whole-joint transplantation. Clin Orthop Rel Res 174: 43-53, 1983

• 11) Shahgaldi BF, Amis AA, Heatley FW, et al: Repair of cartilage lesions using biological implants. J Bone Joint Surg 73-B: 57-64, 1991

• 12) Elves MW: Astudy of the transplantation antigens on chondrocytes from articular cartilage. J Bone Joint Surg 56-B: 178-185, 1974

• 13) Langer F, Gross AE: Immunogenicity of allograft articular cartilage. J Bone Joint Surg 56-A: 297-304, 1974
  pubmed

• 14) Backdahl M, Consiglio V, Falconer B: Reconstruction of the external ear with the use of maternal cartilage. Brit J Plast Surg 7: 263-273, 1954
  pubmed

• 15) Gibson T: The long-term survival of cartilage homografts in man. Brit J Plast Surg 11: 177-187, 1958

• 16) Campbell CJ, Ishida H, Takahashi H, et al: The transplantation of articular cartilage. J Bone Joint Surg 45-A: 1579-1592, 1963
  pubmed

• 17) Chesterman PJ, Smith AU: Homotransplantation of articular cartilage and isolated chondrocytes. J Bone Joint Surg 50-B: 184-197, 1968

• 18) Bentley G, Greer RB III: Homotransplantation of isolated epiphyseal and articular cartilage chondrocytes into joint surfaces of rabbits. Nature 230: 385-388, 1971

• 19) Aston JE, Bentley G: Repair of articular surfaces by allografts of articular and growth-plate cartilage. J Bone Joint Surg 68-B: 29-35, 1986

• 20) Smith AU: Survival of frozen chondrocytes isolated from cartilage of adult mammals. Nature 205: 782-784, 1965

• 21) Wakitani S, Kimura T, Hirooka A, et al: Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. J Bone Joint Surg 71-B: 74-80, 1989

• 22) Kimura T, Yasui N, Ohsawa S, et al: Chondrcytes embedded in collagen gels maintain cartilage phenotype during long-term cultures, Clin Orthop Rel Res 186: 231-239, 1984

• 23) Kawamura S, Wakitani S, Maeda A, et al: Articular cartilage repair-rabbit experiments with a collagen gel-biomatrix and chondrocytes cultured within it. Acta Orthop Scand (in press)

• 24) Brittberg M, Lindahl A, Nilsson A, et al: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. New England J Med 331: 889-895, 1994

• 25) Cuevas P, Burgos J, Baird A: Basic fibroblast growth factor promotes cartilage repair in vivo. Biochem Biophys Res Comm 156;611-618, 1988
  pubmed

• 26) van Beuningen MH, van der Kraan PM, Arntz OJ, et al: Transforming growth factor-β1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte synthesis in the rnurine knee joint. Lavoratory Investigation 71: 279-290, 1994

• 27) Seller R, Haire T, Gaskin A, et al: rhBMP-2 accelerated healing of full-thickness articular cartilage defects. Trans Orthop Res Soc 21: 284, 1996

• 28) Wakitani S, Imoto K, Kimura T, et al: Hepatocyte growth factor facilitates cartilage repair-full thickness articular cartilage defect studied in rabbit knees. Acta Orthop Scand (in press)

治療と副作用

P.215 掲載の参考文献

• 1) Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 38: 151-160, 1995

• 2) Brenann FM, Maini RN, Feldmann M: TNFα-Apivotal role in rheumatoid arthritis? Br J Rheumatol 31: 293-298, 1992

• 3) Keffer J, Probert C, Cazlaris H, et al: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 10: 4025-4031, 1991:

• 4) Brenann FM, Chantry D, Jackson S, et al: Inhibitory effects of TNFα antibodies in rheumatoid arthritis. Lancet ii 244-247, 1989

• 5) Haworth C, Brenann FM, Chantry D, et al: Expression of granulocyte-macrophage colony stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 21: 2575-2579, 1991

• 6) Butler DM, Maini RN, Feldmann M, et al: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNFα antibody with the IL-1 receptor antagonist. European Cytokine Network 6: 225-230, 1995

• 7) Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorate joint disease in murine collagen induced arthritis. Proc Natl Acad Sci USA 89: 9784-9788, 1992
  pubmed

• 8) Elliott MJ, Maini RN, Feldmann M, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36: 1681-1690, 1993

• 9) Maini RN, Elliott MJ, Brenann FM, et al: Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immuno Rev 144: 195-223, 1995

• 10) Paulus HE, Egger ME, Ward JR, et al: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on findings in patients treated with placebo. Arthritis Rheum 33: 477-484, 1990

• 11) Cope AP, Londei M, Chu R, et al: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex;reversal in vivo by anti-TNF anibodies in patients with rheumatoid arthritis. J Clin Invest 94: 749-760, 1994

• 12) Paleolog EM, Hunt M, Elliott MJ, et al: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 39: 1082-1091, 1996

• 13) Scallon BJ, Moore MA, Trinh H, et al: Chimeric anti-TNFα monoclonal antibody, cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 7 (3): 251-259, 1995

• 14) Rankin ECC, Choy EHS, Kassimos D, et al: The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34: 334-342, 1995

• 15) Van Dullemen HM, et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135, 1995
  pubmed

P.223 掲載の参考文献

• 1) 広瀬俊一, 狩野庄吾: 全身性エリテマトーデス (SLE) の病態別治療指針. 厚生省特定疾患自己免疫疾患調査研究班, 1993

• 2) Austin HA, Klippel JH, Balow JE, et al: Therapy of lupus nephritis. Controlled rial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986

• 3) Boumpas DT, Austin HA, Vaughn EM, et al: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephrits. Lancet 340: 741-745, 1992

P.231 掲載の参考文献

• 1) 戸川敦: 多発性骨髄腫. 治療学総論-予後因子-. 日本臨床53: 106-110, 1995

• 2) Alexanian R, Haut A, Khan A: Treatment of multiple myeloma: combination chemotherapy withdifferent melpharan dose regimens. JAMA 208: 1680-1685, 1969

• 3) Kawano M, Hirano T, Matsuda T, et al: Autocrine generation and requirement of BSF-2/IL-6 forhuman multiple myeloma. Nature 322: 83-85, 1988

• 4) Klein B, Zhang XG, Jourdan M, et al: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation interleukin-6. Blood 73: 517-526, 1989
  pubmed

• 5) Kurihara N, Bertolini D, Suda T, et al: IL-6 stimulates osteoclast-like multinucleated cell formation in long term human bone marrow cultures by inducing IL-1 release. J Immunol 144: 4226-4230, 1990
  pubmed

• 6) Hardin J, MacLeod S, Grigorieval, et al: Interleukin-6 prevents dexamethasone-induced myelomacell death. Blood 84: 3063-3070, 1994

• 7) Durie BGM, Salmon SE: Aclinical staging system for multiple myeloma. Correlation of measuredmyeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36: 842-854, 1975

• 8) Greipp PR, Katzmann JA, O'Fallon WM, et al: Value of beta2-microglobulin level and plasma celllabeling indices as prognostic factors in patients with newly diagnosed Inyeloma. Blood 72: 219-223, 1988

• 9) Boccadoro M, Gavarotti P, Fossati G, et al: Low plasma cell 3 (H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smoudering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br J Haematol 58: 689-696, 1984

• 10) Bataille R, Jourdan M, Zhang XG, et al: Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect ofdisease severity in plasma cell dyscrasias. J Clin Invest 84: 2008-2011, 1989

• 11) Bataille R, Boccadoro M, Klein B, et al: C-reactive protein and serum β2 microgrobulin produce a simple and powerful myeloma staging system. Blood 80: 733-737, 1992

• 12) Osgood EE: The survival time of patients with plasmacytic myeloma. Cancer Chemother Rep 9: 1-10, 1960
  pubmed

• 13) Alexanian R, Dimopoulos MA: The treatment of multiple myeloma. N Engl J Med 330: 484-489, 1994

• 14) Ahre A, Bjorkholm M, Mellstedt H, et al: Human leukocyte interferon and intermittent high-dosemelphalan-prednisone administration in the treatment of multiple myeloma: arandomized clinical trial from the Myeloma Group of Central Sweden. Cancer Tret Rep 68: 1331-1338, 1984

• 15) Bensinger WJ, Rowley SD, Demirert, et al: High dose therapy followed by autologoushematopoietic stem-cell infusion for patients with myeloma. J Clin Oncol 14: 1447-1456, 1996

• 16) Gahrton G, Tura S, Ljungman P, et al: Allogeneic bone marrow transplantation in multiplemyeloma. N Engl J Med 325: 1267-1273, 1991

• 17) Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13: 1312-1322, 1995
  pubmed

• 18) Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78, 1993
  pubmed

• 19) Nordon R, Potter M: A macrophage-derived factor required by plasmacytomas for survival andproliferation in vitro. Science 233: 566-569, 1986

• 20) Nishimoto N, Shima Y, Yoshizaki K, et al: Myeloma biology and therapy-present status futuredevelopments. Hematol/Oncol Clin North Amer 11: 159-172, 1997

• 21) Klein B, Wijdenes J, Zhang XG, et al: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198-1204, 1991
  pubmed

• 22) Bataille R, Barlogie B, Lu ZY, et al: Biological effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86: 685-691, 1995
  pubmed

• 23) Sato K, Tsuchiya M, Saldanha J, et al: Reshaping a human antibody to inhibit the interleukin-6 dependent tumor cell growth. Cancer Res 53: 851-856, 1993
  pubmed

• 24) Nishimoto N, Ogata A, Shima Y, et al: Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 177: 1343-1347, 1994

P.238 掲載の参考文献

• 1) Abatangelo G, O'Regan M: Hyaluronan: biological role and function in articular joints. Eur J Rheumatol Inflamm 15: 9-16, 1995

• 2) Scott JE: Hyaluronan, multum in parvo. Eur J Rheumatol Inflamm 15: 3-8, 1995

• 3) 後藤 眞: ヒアルロン酸の生理的役割と疾患. 炎症15: 105-113, 1995

• 4) 小出 純, 伊藤達也: RAの滑膜細胞上のCD44分子とヒアルロン酸Rheumatology Today 9: 3-9, 1996

• 5) 山田 登, 宇月美加, 力丸 腸ら: 血中ヒアルロン酸濃度と慢性関節リウマチの病態. リウマチ34: 752-760, 1994

• 6) 今中啓之, 武井修治, 重森政彦ら: 若年性関節リウマチにおける血中フアルロン酸の意義. リウマチ34: 360 (抄), 1994

• 7) 松浦 豪, 山中健輔, 橋本三四郎ら: 血中ヒアルロン酸, 慢性関節リウマチを中心として. 臨床検査38: 805-809, 1994

• 8) 中園 清, 村澤 章, 遠山知香子ら: 慢性関節リウマチ患者の血中ヒアルロン酸について. 中部リウマチ25: 10-11, 1994

• 9) 河村禎人, 鳥塚之嘉, 橋本英雄ら: 慢性関節リウマチにおける骨髄ストローマ細胞によるヒアルロン酸の産生. 日整会誌69: S-1426 (抄), 1995

• 10) 市場厚志, 岸本郁男, 上野征夫ら: 慢性関節リウマチ患者における血清ヒアルロン酸濃度. リウマチ36: 311 (抄), 1996

• 11) 田辺 学, 石山香恵, 諏訪 昭ら: 慢性関節リウマチにおける血清および尿中ヒアルロン酸濃度. 炎症16: 97-102, 1996

• 12) 澤井高志, 宇月美加, 山田登: ヒアルロン酸結合蛋白 (HABP) を利用した血清ヒアルロン (HB) 濃度測定と慢性関節リウマチ (RA) における測定の意義, 第27回口本結合組織学会抄録p47, 1995

• 13) 傅田澄美子, 山口敏二郎, 並木 脩: 変形性膝関節症および慢性関節リウマチ患者関節液の軟骨グルコサミノグリカン遊離作用とそれに対する高分子量ヒアルロン酸ナトリウム (SL/1010) の抑制作用. 薬理と治療 21: 165-172, 1993

• 14) 鵜狩善: , 藤井克之, 室田景久: 慢性関節リウマチに対する高分子ヒアルロン酸の治療効果-コラーゲン関節炎を病態モデルとしての検討-, 日関外誌12: 351-366, 1993

• 15) Fukuda K, Dan H, Takayama M, et al: Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-2. Pharmacol Exp Therap 277: 1672-1675, 1996

• 16) 松原 司, 高橋信男, 水野耕作: RA滑膜細胞の塩基性線維芽細胞増殖因子産生に対するヒアルロン酸の影響, 臨床リウマチ5: 247-250, 1994

• 17) 山下 泉, 熱田祐司, 島崎俊司ら: ブラジキニンを用いたラット膝関節察痛モデルにおけるプロスタグランジンE, とヒアルロン酸ナトリウムの影響. 日整会誌69: 735-743, 1995

• 18) 堀越正智, 宗園 聡, 山口公一ら: 慢性関節リウマチにおける関節軟骨破壊に対するSubstance Pとピアルロン酸の影響. 日整会誌69: S1745 (抄), 1995

• 19) 石西 貴, 緒方公介, 池田 実: 慢性関節リウマチに対するヒアルロン酸注入療法が関節液中の炎症マーカーに及ぼす影響. リウマチ36: 311 (抄), 1996

• 20) 大島良雄, 並木 脩, 東威ら: 慢性関節リウマチに対する高分了ヒアルロン酸ナトリウム (SPH) の関節腔内注射療法. 薬理と治療15: 1349-1365, 1987

• 21) 村田紀和, 櫛谷昭一・, 青野充志ら: 変形性関節症および慢性関節リウマチ膝関節に対する高分了ヒアルロン酸ナトリウム注入療法. 臨床リウマチ1: 375-380, 1988

• 22) 喜多 寛, 田中清介, 富原光雄ら: RA膝に対するヒアルロン酸ナトリウム注入療法. 臨床リウマチ2: 137-142, 1989

• 23) 中村亜矢子ら: 慢性関節リウマチ (RA) 膝関節液に及ぼす高分子ヒアルロン酸ナトリウム (アルツ) の生化学的影響の解析。薬理と治療18: 2335-2340, 1990

• 24) 上好昭孝, 星野 潤: 慢性関節リウマチ膝に対する高分子ヒアルロン酸ナトリウム(SPH)の関節内注入療法. 臨床リウマチ3: 303-308, 1990

• 25) 萩野哲男, 中島育昌, 佐藤英昭ら: 慢性関節リウマチに対するヒアルロン酸ナトリウムの関節内注入. 日関外誌17: 253-258, 1993

• 26) 山田 登, 宇月美加, 大沼英子ら: 慢性関節リウマチに対する高分子量ヒアルロン酸ナトリウム(NRD101)の関節内投与による局所症状と滑膜組織に与える影響. 炎症14: 303-311, 1994

• 27) 松野博明, 酒井清司, 辻 陽雄ら: RA患者における高分了ヒアルロン酸 (HA) の効果. 中部リウマチ26: 40-41, 1995

• 28) 後藤 眞: 高分子ヒアルロン酸ナトリウム (NRD101) の慢性関節リウマチに対する臨床効果と関節液分析. 臨床リウマチ6: 33-49, 1994

• 29) 田巾清介, 山本 眞, 小松原良雄: 高分子ヒアルロン酸ナトリウム (NRD101) の慢性関節リウマチに対する臨床評価-多施設共同による第三相比較臨床試験-. 臨床リウマチ5: 304-332, 1994

P.246 掲載の参考文献

• 1) Rosenberg EF, Baggenstoss AH, Hench PS: The causes of death in thirty cases of rheumatoid arthritis. Ann Int Med 20: 903-919, 1944

• 2) Reilly PA, Cosh JA, Maddison PJ, et al: Mortality and survival in rheumatoid arthritis: a 25 year and prospective study of 100 patients. Ann Rheum Dis 49: 363-369, 1990
  pubmed

• 3) 小林絢三: 非ステロイド性抗炎症剤による胃粘膜障害. 日本醫事新報3787: 86, 1996

• 4) Myllykangas-Luosujarvi R, Aho K, Isomaki H: Motality in rheumatoid arthritis. Arthritis Rheum 25: 193 . 202, 1995

• 5) 塩川優: 延永 正, 斎藤輝信ほか: 非ステロイド性抗炎症剤による上部消化管障害に関する疫学調査, リウマチ31: 96-111, 1991

• 6) 斎藤輝信: 非ステロイド性抗炎症薬療法. リウマチ科17 (3): 235-241, 1997

• 7) Felden M (Ed): Gastroenterology and hepatology, Volume 3. Stomach and duodenum, pp6-10, New York, Churchill Livingstone, 1996

• 8) 村上元庸: 高齢者の慢性疾患診療のポイント-胃腸疾患. 日本醫事新報3827: 40-43, 1997

• 9) Voskuyl AE, Van de Laar MAFJ, Moens HJB, et al: Extra-articular manifestations of rheumatoid arthritis: risk factors for serious gastrointestinal events. Ann Rheum Dis 52: 771-775, 1993

• 10) Fries JF: NSAID gastropathy;The second most deadly rheumatic desease? Epidemiology and risk appraisal. J Rheumatol (suppl 28) 18: 6-1, 1991

• 11) Myllykangas-Luosujarvi R, Aho K, Isomaki H: Death attributed to antirheumatic medication in a nationwide series of 1, 666 patients with rheumatoid arthritis who have died. J Rheumatol 22: 2214-2217, 1995

• 12) Someville K, Faulker G, Langman M: Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1: 462-464, 1986

• 13) 大田 寛, 七川歡次, 前田 晃: 慢性関節リウマチの死因調査 (370死亡例). 平成7年度, 特定疾患調査研究報告書 (大阪骨・関節難病研究会) 骨pp44-65, 大阪府環境保健部大阪府特定疾患研究会, 平成8年3月, 1996

• 14) Bjarnason I, Hayllar J, Macpherson AJ, et al: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterogy 104: 1832-1847, 1993

• 15) 浅香正博, Graham DY: 対談 転換期を迎えた潰瘍治tS-NSAIDs起因性潰瘍を中心に-. GI Research 4: 681 688, 1996

• 16) 古谷武文, 都外川新, 中島亜矢了ら: 慢性関節リウマチにおける低用量メトトレキサート療法の有害事象- 自験例276例での検討-. リウマチ36: 746-752, 1996

• 17) 大曽根康夫, 岡野 裕, 亀田秀人ら: 慢性関節リウマチにおけるメトトレキサート療法の副作用-とくに汎血球減少症と間質性肺炎例の背景因子に関する検討-. リウマチ37: 16-23, 1997

• 18) Keisu M, Ekman E: Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features and estimation of its incidence. Eur J Clin Pharmacol 43: 215-218, 1992
  pubmed

• 19) Owen D, Waller M, Toone E: Rheumatoid disease and malignancy. Arthritis Rheum 10: 302-303, 1967

• 20) Isomaki HA, Hukulinen T, Joutsenlahti U: Excess risk of lymphomas, 1eukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 31: 691-696, 1978

• 21) 宮本健央, 奥田恭章, 小山 徹ら: 日本人の慢性関節リウマチ患者における悪性腫瘍の発生. リウマチ96: 741-745, 1996

• 30) 小松原良雄: RAに対するヒアルロン酸の臨床. Rheurnatology Today 9: 10-13, 1996

手術

P.253 掲載の参考文献

• 1) MacKenzie JR, Kelley SS, Johnston RC: Total hip replacement for coxarthrosis secondary to congenital dysplasia and dislocation of the hip. Long-term result. J Bone Joint Surg 78-A: 55-61, 1996
  pubmed

• 2) Martell JM, Pierson RH, Jacobs JJ, et al: Primary total hip reconstruction with a titanium fiber coated prosthesis inserted without cement. Ibid 75-A: 554-571, 1993

• 3) Maloney WJ, Harris WH: Comparison of a hybrid with an uncemented total hip replacement. A retrospective matched-pair study. Ibid 72. A: 1349-1352, 1990

• 4) Wixson RL, Stulberg SD, Mehlhoff M: Total hip replacement with cemented, uncemented and hy-brid prostheses. A comparison of clinical and radiographic results at two to four years. Ibid 73-A: 257-270, 1991

• 5) 林和生: 人工材料 (人工骨) の臨床応凧ハイドロキシアパタイトコーティングチタン合金製人工股関節 について. 骨・関節・靱帯8: 437-444, 1995

• 6) Willert HG, Bertram H, Buchorn GH: Osteolysis in alloarthroplasty of the hip. The role of ultra-high molecular weight polyethylene wear particles. Clin Orthop 258: 108-121, 1990

• 7) 井上康二: 人工関節のゆるみとリウマトイド肉芽. リウマチ病セミナー (七川歡次監修), pp295-305, 大阪, 永井書店, 1994

P.260 掲載の参考文献

• 1) Wiltse LL, Guyer RD, Spencer CW, et al: Alar transeverse process impingement of the L5 spinal nerve: the far-out syndrome. Spine 9: 31-41, 1984

• 2) Burton CV: Lumber Spine Surgery. Baltimore, Williams&Wilkins, pp202-207, 1988

• 3) Kikuti S, Hasue M, Nisiyama K, et al: Anatomic and clinical studies of radicular symptons. Spine 9: 23-30, 1984

• 4) 小野村敏信: 腰椎分離すべり症に対する手術術式の変遷とその問題点. 整形外科Mook 33: 120-131, 1980

• 5) 馬場逸志: 後側法固定術一Without instrumentation: 変性, 分離すべり症. 腰椎シンポ5講演記録集, Intermedd Inc, Tokyo, pp25-32, 1994

• 6) 宮地芳樹, 小野村敏信, 渡辺秀男ら: 重度脊椎すべり症に対する後方からの整復固定術とその問題点. 臨床整形外科25: 527-535, 1990

• 7) 宮地芳樹, 小野村敏信, 速水英夫ら: 脊椎分離すべり症 (MeyerdinaIII, IV) に対する手術的治療. 脊椎脊髄7: 341-346, 1994